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Abstract
Triggering receptor expressed on myeloid cells 2 (TREM2) is essen-
tial for the transition of homeostatic microglia to a disease-asso-
ciated microglial state. To enhance TREM2 activity, we sought to
selectively increase the full-length protein on the cell surface via
reducing its proteolytic shedding by A Disintegrin And Metallopro-
teinase (i.e., a-secretase) 10/17. We screened a panel of mono-
clonal antibodies against TREM2, with the aim to selectively
compete for a-secretase-mediated shedding. Monoclonal antibody
4D9, which has a stalk region epitope close to the cleavage site,
demonstrated dual mechanisms of action by stabilizing TREM2 on
the cell surface and reducing its shedding, and concomitantly acti-
vating phospho-SYK signaling. 4D9 stimulated survival of macro-
phages and increased microglial uptake of myelin debris and
amyloid b-peptide in vitro. In vivo target engagement was demon-
strated in cerebrospinal fluid, where nearly all soluble TREM2 was
4D9-bound. Moreover, in a mouse model for Alzheimer’s disease-
related pathology, 4D9 reduced amyloidogenesis, enhanced micro-
glial TREM2 expression, and reduced a homeostatic marker,
suggesting a protective function by driving microglia toward a
disease-associated state.
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Introduction
Alzheimer’s disease (AD) and related disorders are devastating
diseases threatening our aging society, and still, no cure is available.
Since a number of recent clinical trials using amyloid b-peptide (Ab)-
based therapeutic approaches failed to improve cognition or even
worsened the clinical outcome of patients (Egan et al, 2019), novel
targets are desperately needed. Importantly, it appears that anti-Ab
therapeutics may have to be administered decades before symptom
onset, since at the time patients are enrolled in clinical studies they
are amyloid positron emission tomography (PET)-positive (Sevigny
et al, 2016) even if they have not yet developed overt dementia. We
therefore need to develop strategies to interfere with the amyloid
cascade immediately after it has been initially triggered by Ab and
may become independent of its further de novo production.
In addition to the selective deposition of amyloidogenic proteins,
neuroinflammation associated with microgliosis is a common
feature of many neurodegenerative disorders (Ransohoff, 2016).
Recent genome-wide association studies strongly substantiated a
central role of innate immunity for neurodegeneration by identifying
a number of risk variants in genes that are exclusively expressed
within microglia in the brain. Among them, coding variants in the
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triggering receptor expressed on myeloid cells 2 (TREM2) increase
the risk for late-onset AD as much as the apolipoprotein e4 allele
(Guerreiro et al, 2013; Jonsson & Stefansson, 2013; Jonsson et al,
2013; Rayaprolu et al, 2013; Borroni et al, 2014; Cuyvers et al,
2014). The disease-associated variants appear to cause a loss of
function of TREM2 through a variety of mechanisms, including inhi-
bition of cellular maturation of TREM2, destroying essential lipid
binding sites within the immunoglobulin region of the ectodomain,
and enhancing its shedding (Kleinberger et al, 2014, 2017; Mazaheri
et al, 2017; Schlepckow et al, 2017; Ulland et al, 2017; Song et al,
2018). Full-length TREM2, in association with DAP12, forms a
heteromeric complex required to activate phospho-SYK signaling
(Colonna, 2003). Signaling appears to be terminated by a-secretase-
mediated shedding of the TREM2 ectodomain (Fig 1A) (Wunderlich
et al, 2013; Kleinberger et al, 2014), although very recent data
suggest that soluble TREM2 (sTREM2) may also have signaling
functions (Zhong et al, 2017, 2019), and requires further investiga-
tion. Loss of TREM2-mediated signaling locks microglia in a homeo-
static state and inhibits their transition to disease-associated
microglia (DAM) (Krasemann et al, 2017; Mazaheri et al, 2017),
which are phenotypically characterized by enhanced migration,
chemotaxis, and phagocytosis (Keren-Shaul et al, 2017; Mazaheri
et al, 2017). Furthermore, lack of functional TREM2 appears to be
associated with reduced cellular proliferation and death of phago-
cytes as well as reduced energy metabolism and cerebral blood flow
in mice (Ulland et al, 2015, 2017; Kleinberger et al, 2017). TREM2
has been shown to be involved in lipid sensing, a function which is
diminished by the AD-associated TREM2 R47H variant (Wang et al,
2015). Furthermore, loss of TREM2 results in downregulation of
genes involved in lipid metabolism (Keren-Shaul et al, 2017; Griciuc
et al, 2019). Consistent with these observations, TREM2 appears
to be required for elimination of damaged myelin by microglia
(Cantoni et al, 2015). Moreover, TREM2-deficient microglia were
shown to be overloaded with cholesterol esters (CEs) as well as
other lipid species as a result of chronic phagocytic challenge of
myelin debris induced by a cuprizone diet (Nugent et al, 2019),
indicating that TREM2 is important for lipid processing in addition
to phagocytosis.
Quantitative analyses of the cleaved sTREM2 ectodomain in the
cerebrospinal fluid of patients with sporadic and autosomal domi-
nant AD (ADAD) revealed enhanced levels at the mild cognitive
impairment stage (Suarez-Calvet et al, 2016b, 2019) and up to
5 years before the estimated onset of ADAD (Suarez-Calvet et al,
2016a), respectively. Moreover, sTREM2 positively correlates with
total tau and phospho-tau but not with Ab (Suarez-Calvet et al,
2016b). Thus, CSF sTREM2 seems to be associated with tau pathol-
ogy. Moreover, microglial activation and associated cellular func-
tions are protective for cognition in a mouse model of AD (Focke
et al, 2019), and ameliorate retinal degeneration (O’Koren et al,
2019). Furthermore, high levels of CSF sTREM2 predict a better
outcome of cognition and reduced hippocampal shrinkage in the
Alzheimer’s disease neuroimaging initiative cohort (Ewers et al,
2019). Taken in combination with the observation that TREM2 loss
of function increases AD risk, this suggests that enhancing TREM2
signaling represents a therapeutic strategy that is downstream of the
initial Ab-mediated trigger of the amyloid cascade.
Since a-secretase-mediated shedding of TREM2 (Kleinberger
et al, 2014; Schlepckow et al, 2017; Thornton et al, 2017) is suffi-
cient to abrogate cell-autonomous signaling, we hypothesized that
elevating TREM2 levels on the cell surface would enhance poten-
tially disease-modulating microglial functions. Indeed, inhibition of
a-secretase activity with a protease inhibitor enhanced the phago-
cytic capacity of microglial-like BV2 cells (Kleinberger et al, 2014).
However, a-secretase competes with the amyloidogenic pathway
and limits Ab production (Haass & Selkoe, 1993); therefore, its inhi-
bition in AD would be not be efficacious. Moreover, a disintegrin
and metalloproteinase (ADAM, i.e., a-secretase) 10 and ADAM17
cleave numerous substrates within the brain, many of which
▸Figure 1. Screening and molecular characterization of anti-mouse TREM2 antibodies.A Schematic representation of TREM2 processing by ADAM10/17. Cleavage occurs C-terminal of residue His 157. The entire ectodomain (residues 19–171) was used for
immunization of rats to generate TREM2 antibodies. CTF, C-terminal fragment; sTREM2, soluble TREM2.
B Immunoblot analysis of membrane fractions of HEK293 Flp-In cells stably overexpressing both mouse TREM2 and mouse DAP12 upon treatment with 4D9 antibody
reveals increased levels of membrane-bound TREM2 similar to what can be achieved by ADAM protease inhibition using the GM6001 inhibitor. An isotype antibody
was used as a negative control. Calnexin served as a loading control. Levels of membrane-bound TREM2 were quantified by MSD ELISA. Data represent the
mean  SEM (n = 3). One-way ANOVA, Tukey’s post hoc test; P (DMSO vs GM) = 0.0011; P (DMSO vs isotype) = 0.992; P (isotype vs 4D9) = 0.0005; n.s., not
significant.
C Immunoblot analysis of conditioned media from HEK293 Flp-In cells stably overexpressing both mouse TREM2 and mouse DAP12 upon treatment with 4D9 antibody
reveals decreased levels of sTREM2 similar to what can be achieved by ADAM protease inhibition using the GM6001 inhibitor. An isotype antibody was used as a
negative control. sAPPa served as a loading control. Note that heavy and light chains of the antibodies used for treatment are also detected and annotated. Levels of
sTREM2 were quantified by MSD ELISA. Data represent the mean  SEM (n = 3). One-way ANOVA, Tukey’s post hoc test; P (DMSO vs GM) < 0.0001; P (DMSO vs
isotype) = 0.6372; P (isotype vs 4D9) < 0.0001; n.s., not significant.
D 4D9 antibody selectively detects TREM2 on the cell surface of HEK293 Flp-In cells stably overexpressing mouse TREM2 and mouse DAP12. An anti-HA antibody was
used as a positive control, while empty vector-transfected HEK293 Flp-In cells were used as a negative control. Scale bar = 10 lm.
E Peptide ELISAs detect anti-mouse TREM2 antibody binding to tiled stalk region peptides, full-length stalk peptide, or a truncated ADAM cleavage site peptide. The
binding epitope of 4D9 antibody is located 12-amino acids N-terminal of the ADAM cleavage site at His 157.
F Sequence comparison of mouse TREM2 and human TREM2 shows substantial sequence conservation around the 4D9 epitope (upper panel). Immunoblot analysis
demonstrates that antibody 4D9 is highly specific for mouse TREM2 and does not detect human TREM2 or mouse TREM1 (lower panel).
G 4D9 binding to the mouse TREM2 ECD is competed off by a stalk region peptide. A competition ELISA demonstrates that a dose titration of stalk peptide reduces
binding of 4D9 to TREM2 ECD with an EC50 of 1.3 lM. Data represent the mean  SEM (n = 3). ECD, extracellular domain.
H Surface plasmon resonance binding kinetics of increasing concentrations of 4D9 antibody to mouse TREM2 ECD evaluated by Biacore, kon = 5.9 × 10
5 M1 s1,
koff = 4.0 × 10
5 s1, KD = 68 pM. 4D9 binding to human TREM2 or mouse TREM1 was undetectable.
Data information: Statistical evaluations are displayed as follows: **P < 0.01; ***P < 0.001; ****P < 0.0001.
Source data are available online for this figure.
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stimulate essential physiological signaling pathways (Kuhn et al,
2016). We therefore sought to selectively inhibit TREM2 cleavage
without affecting shedding of other ADAM10/17 substrates. We and
others have previously identified the cleavage site of TREM2 after
His 157 within the stalk region of TREM2 (Feuerbach et al, 2017;
Schlepckow et al, 2017; Thornton et al, 2017) (Fig 1A). In this
study, we screened for monoclonal antibodies binding to the stalk
region encompassing the cleavage site with the purpose of stabiliz-
ing membrane-bound TREM2 and selectively enhancing TREM2-
dependent protective functions in microglia.
Results
Screening and molecular characterization of
anti-TREM2 antibodies
To identify antibodies capable of increasing TREM2 on the cell surface,
we raised monoclonal antibodies to the recombinantly expressed ecto-
domain of mouse TREM2 (amino acids 19–171; Fig 1A). Among the
antibodies tested, 4D9, a rat IgG2a antibody, was selected for addi-
tional studies based on its ability to significantly enhance cell
membrane TREM2 levels and to reduce sTREM2 levels similar to an
ADAM protease inhibitor (Fig 1B and C). Immunohistochemistry
showed that the 4D9 antibody bound to the cell surface of mouse
TREM2-expressing HEK293 cells, while empty vector-expressing
control cells did not show staining (Fig 1D). Antigen mapping using
tiling peptides along the stalk region of TREM2 revealed specific bind-
ing of 4D9 to N-DAGDLWVPE, a 9-amino acid peptide N-terminal to
the ADAM cleavage site (Fig 1E). Although this epitope shows
substantial sequence similarities to human TREM2 (Fig 1F), 4D9 did
not detect recombinant human TREM2 by Western blotting (Fig 1F).
Furthermore, consistent with a lack of sequence conservation of the 9-
amino acid region between mouse TREM1 and TREM2, 4D9 binding
to mouse TREM1 was not detected (Fig 1F), demonstrating that 4D9 is
indeed selective for mouse TREM2. To further confirm specific binding
of 4D9 to the stalk region epitope, peptide competition experiments
were performed. This demonstrated efficient competition of a TREM2
stalk peptide for 4D9 binding to the extracellular protein (Fig 1G).
Antibody–antigen affinity was determined by surface plasmon reso-
nance (SPR) demonstrating a monovalent KD of 68pM for mouse
TREM2 (Fig 1H). Consistent with the Western blot data (see Fig 1F),
human TREM2 and mouse TREM1 did not result in any SPR response
(Fig 1H).
High-affinity cell-surface TREM2 binding was established for 4D9
using HEK293 cells stably expressing TREM2. A dose response
demonstrated a cell binding EC50 of 0.29 nM, while an isotype control
antibody did not show measurable binding (Fig 2A). Next, we gener-
ated Fab fragments of 4D9, which specifically bound cell-surface
TREM2 on HEK293 cells with an EC50 of 0.17 nM (Fig 2A). In vitro
peptide cleavage assays using recombinant ADAM17 revealed that the
full-length 4D9 antibody, as well as 4D9 Fab, significantly blocked
cleavage of a TREM2 stalk peptide substrate (Fig 2B). Thus, 4D9
appears to sterically hinder access of ADAM17 to its substrate.
However, in a cell-based assay, only full-length IgG 4D9 antibody, but
not 4D9 Fab, potently reduced shedding of TREM2 in a dose-depen-
dent manner with an EC50 of 2.3 nM (Fig 2C). Given that 4D9
reduced shedding and enhanced cell-surface levels of full-length
TREM2, we next evaluated the effects on downstream signaling. We
therefore investigated p-SYK activity in the presence or absence of
4D9 and an isotype control in HEK293 cells expressing mouse TREM2
and its signaling adapter DAP12. This revealed a dose-dependent
increase in p-SYK upon addition of 4D9 but not 4D9 Fab to the culture
media of the cells (Fig 2D). Furthermore, anionic liposome ligand
(Shirotani et al, 2019) stimulated TREM2 signaling 2.3-fold by full-
length 4D9 but not by 4D9 Fab or the isotype control (Fig 2E). These
data therefore suggest that the monoclonal antibody 4D9 enhances
TREM2-dependent signaling via bivalent binding which cross-links
TREM2 on the plasma membrane. Bivalent TREM2 binding is
required for both signaling and shedding blocking mechanisms of
TREM2 antibody function, potentially as a result of the inability of
proteases to accept dimeric substrates (Fig 2F).
4D9 antibody modulates TREM2 function in primary
macrophages and microglia
We next investigated whether TREM2-dependent functions of
myeloid cells can be modulated by 4D9. For these studies, 4D9
▸Figure 2. 4D9 antibody stimulates TREM2-dependent SYK signaling and blocks ADAM17-mediated TREM2 shedding.A Flow cytometry dose–response curve for cell binding of 4D9 mAb (EC50 = 0.29 nM), 4D9 Fab (EC50 = 0.17 nM), and isotype to HEK cells stably overexpressing mouse
TREM2. Data represent the mean  SEM (n = 2).
B In vitro ADAM17 sheddase activity is blocked by 4D9-effectorless mAb and 4D9 Fab fragment but not an isotype control. Fluorescence polarization of FAM-conjugated
TREM2 stalk peptide was detected in the presence or absence of ADAM17 and 4D9 mAb, 4D9 Fab, and isotype control. Data represent the mean  SEM (n = 6). One-
way ANOVA, Tukey’s post hoc test; P (4D9 Fab vs 4D9 mAb) = 0.8855; P (4D9 Fab vs uncleaved) < 0.0001; P (4D9 mAb vs uncleaved) < 0.0001; n.s., not significant.
C ELISA-mediated quantification of sTREM2 in conditioned media from HEK293 cells stably overexpressing mouse TREM2 treated with a dose titration of 4D9 mAb
(EC50 = 2.3 nM), 4D9 Fab, or isotype for 18 h. Data represent the mean  SEM (n = 3).
D AlphaLISA-mediated quantification of p-SYK levels in HEK293 Flp-In cells stably overexpressing mouse TREM2 and mouse DAP12 treated with a dose titration of 4D9
mAb, 4D9 Fab, or isotype for 5 min. Data represent the mean  SEM (n = 3).
E AlphaLISA-mediated quantification of p-SYK levels in HEK293 Flp-In cells stably overexpressing mouse TREM2 and mouse DAP12 or empty vector treated with
1 mg/ml POPC/POPS liposomes and 20 lg/ml 4D9 mAb, 4D9 Fab, or isotype for 5 min. p-SYK levels were also determined for cells treated with liposomes only. Data
represent the mean  SEM (n = 3). Two-way ANOVA, Tukey’s post hoc test (cell line effect: F1,16 = 365.7, P ≤ 0.0001; treatment effect: F3,16 = 39.35, P < 0.0001; cell
line × treatment effect: F3,16 = 38.75, P < 0.0001); P (no Ab vs isotype) = 0.6218; P (no Ab vs 4D9 mAb) < 0.0001; P (no Ab vs 4D9 Fab) = 0.7301; P (isotype vs 4D9
mAb) < 0.0001; P (isotype vs 4D9 Fab) > 0.9999; P (4D9 mAb vs 4D9 Fab) < 0.0001; n.s., not significant.
F Schematic representation of the proposed mechanism of action of antibody 4D9. Binding of 4D9 to TREM2 leads to receptor clustering on the cell surface, thereby
driving downstream p-SYK signaling. At the same time, cell-surface levels are enhanced by inhibition of ectodomain shedding, potentially because of the inability of
proteases to cleave dimeric substrates.
Data information: Statistical evaluations are displayed as follows: ***P < 0.001; ****P < 0.0001.
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was sequenced and reformatted onto an effectorless human IgG1
backbone carrying mutations that abolish effector function to
avoid confounds of off-target impact of FcR interactions on
primary myeloid cells (for details, see Materials and Methods). To
demonstrate that 4D9 binds endogenous cell-surface TREM2 in
myeloid cells, bone marrow-derived macrophages (BMDMs) were
incubated with biotinylated 4D9 or isotype control antibody. Cell-
surface binding of biotinylated 4D9 was confirmed by FACS with
fluorophore-conjugated streptavidin detection and found to be
statistically significant on BMDM differentiated from three wild-
type mice compared with an isotype control (Fig 3A). Binding was
not detected on BMDM from three TREM2 KO mice, confirming
the specificity of this interaction (Fig 3A). We then examined the
impact of 4D9 on TREM2 shedding by Western blotting of
membrane fractions isolated from six independent BMDM prepara-
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Figure 3. 4D9 antibody modulates TREM2 expression in macrophages and stimulates survival.
A Flow cytometry detection of cell-surface binding of 4D9 (blue) and isotype (green) to wild-type and Trem2/ mouse bone marrow-derived macrophages.
Representative histograms are shown as MFI (mean fluorescent intensity). Graphs represent the median signal intensity  SEM (n = 3). Student’s t-test (two-tailed);
Trem2+/+: P = 0.0005; Trem2/: P = 0.4435; n.s., not significant.
B Immunoblot analysis of membrane fractions of bone marrow-derived macrophages (BMDMs) upon treatment with 4D9 antibody reveals increased levels of
membrane-bound TREM2 relative to an isotype antibody. BMDMs from TREM2 knockout mice were included to show the specificity of the anti-TREM2 antibody.
Calnexin served as a loading control. Levels of membrane-bound TREM2 were quantified by MSD ELISA. TREM2 antibody clone 5F4 was used for detection. Data
represent the mean  SEM (n = 5–6). Unpaired t-test (two-tailed) with Welch’s correction; P < 0.0001. No gender-specific differences could be observed.
C Immunoblot analysis of sTREM2 in conditioned media from BMDM upon treatment with 4D9 and isotype antibodies. BMDMs from TREM2 knockout mice were
included to show the specificity of the anti-TREM2 antibody. Soluble APP served as a loading control. Note that heavy and light chains of the antibodies used for
treatment are also detected and annotated as follows: Ab hc, antibody heavy chain; Ab lc, antibody light chain. Levels of sTREM2 were quantified by MSD ELISA.
TREM2 antibody clone 5F4 was used for detection. Data represent the mean  SEM (n = 6). Unpaired t-test (two-tailed) with Welch’s correction; P < 0.0001. No
gender-specific differences could be observed.
D Wild-type, Trem2+/, and Trem2/ BMDMs were plated in low concentration of M-CSF on 4D9 or isotype-coated wells for 5 days, and cellular ATP levels were
measured by luminescence detection to indicate cell viability. 4D9 and isotype data for each genotype represent the mean  SEM (n = 2 and n = 1, respectively).
Data information: Statistical evaluations are displayed as follows: ***P < 0.001; ****P < 0.0001.
Source data are available online for this figure.
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full-length TREM2 (Fig 3B) and reduced levels of sTREM2 in
conditioned media (Fig 3C). Thus, 4D9 reduces shedding and
increases TREM2 on the cell surface of BMDMs.
To study functional consequences of 4D9 treatment, we investi-
gated survival of BMDMs after M-CSF withdrawal. BMDMs were
cultured in low M-CSF concentrations in the media on plates coated
with increasing amounts of 4D9 for 5 days, and the total number of
cells present was detected by total ATP quantification. This revealed
that 4D9 increased cell survival of BMDMs in a potent and dose-
dependent manner with an EC50 of 1.7 nM, whereas the control
antibody failed to rescue survival defects induced by growth factor
withdrawal (Fig 3D). Next, we asked whether a partial loss of func-
tion of TREM2 can also be rescued by 4D9. To do so, we treated
BMDMs derived from heterozygous TREM2 knockout animals. This
revealed that 4D9 significantly increased survival of BMDMs after a
partial loss of function of TREM2 with an EC50 of 1.5 nM although
not to the extent observed in TREM2 wild-type cells (Fig 3D). Taken
together, these findings demonstrate that the 4D9 antibody
enhances macrophage survival and increases cell-surface TREM2
via a dual mechanism of action: reduction in shedding by ADAM10/
17 and enhancement of receptor signaling.
We next investigated whether 4D9 enhances TREM2-dependent
functions in microglia. First, we tested whether 4D9 specifically
detects TREM2 on the surface of microglia. Indeed, 4D9 selectively
binds to the cell surface of primary microglia from wild-type mice,
whereas no binding is observed to microglia derived from a
Trem2/ (Fig 4A). Moreover, addition of antibody 4D9 to the
media of primary microglia significantly increased the percentage of
both myelin (Fig 4B and C) and Ab42 (Fig 4B and D)-positive cells,
while Escherichia coli uptake remained unaltered with 4D9 treat-
ment (Fig 4B and E). Thus, 4D9 enhances TREM2-dependent func-
tions in myeloid phagocytes of the periphery and the central
nervous system.
Pharmacokinetics and in vivo evidence of 4D9 target engagement
We first evaluated the pharmacokinetics of the 4D9-effectorless anti-
body compared with an isotype control in wild-type mice. Plasma
levels of human IgG were evaluated at 1 and 24 h, and 4 and 7 days
after 10 mg/kg intravenous tail injection. 4D9 demonstrated periph-
eral clearance equivalent to that of a normal IgG (Fig 5A), and no
evidence for an immune response to the humanized 4D9 was
observed on this timescale. As expected, brain antibody 4D9
concentrations were much lower than plasma (Fig 5B).
To provide in vivo evidence that levels of antibody in brain were
sufficient for TREM2 target engagement (TE), we determined the
amount of 4D9-bound sTREM2 relative to total sTREM2 present in
the cerebrospinal fluid (CSF) from dosed wild-type mice at various
time points post-dose (Fig 5C). We developed a CSF-based antibody
bound: total sTREM2 assay as it is a clinically translatable approach
to demonstrate TREM2 TE with a relevant biofluid, and can be
connected to further pre-clinical evidence of brain microglial
response. We found that a single injection of 50 mg/kg led to almost
complete saturation of sTREM2 with antibody 4D9 after 24 h, which
gradually reduced to 50% 10 days following a single dose of 4D9
(Fig 5D). In a second study, analysis of the fraction of total sTREM2
bound to 4D9 in CSF of wild-type mice (Fig 5C) after antibody doses
ranging from 0.1 lg/kg to 50 mg/kg showed that full engagement
of CSF sTREM2 can be achieved 24 h after a single dose of
10 mg/kg (Fig 5E). Taken together, these findings indicate robust
TE of 4D9 in vivo.
4D9 antibody modulates TREM2 functions within the brain
To provide direct evidence that 4D9 modulates TREM2 and its func-
tions within the brain, we measured the total level of TREM2 in the
brain of wild-type mice 24 h after injecting 10, 50, or 100 mg/kg of
4D9 antibody. This revealed that 4D9 increased total brain TREM2
in a dose-dependent manner (Fig 5F), suggesting that antibodies
with mechanisms similar to 4D9 could be used to modulate TREM2
functions in vivo. To determine the impact of 4D9 in a disease-rele-
vant model, 6-month-old APP knock-in mice (Saito et al, 2014) and
wild-type mice were treated with 50 mg/kg of antibody 4D9 or an
isotype control in three-day intervals over a 10-day duration
(Fig 6A). No difference in TREM2 expression of wt mice was
observed upon 4D9 treatment, which may be due to the lower sensi-
tivity of immunohistochemistry as compared to quantitative ELISA
determinations shown in Fig 5F. Control-treated APP knock-in mice
showed elevated TREM2 expression as compared to non-transgenic
C57BL6 mice (Fig 6B and C), reflecting a shift to a disease-asso-
ciated state (Krasemann et al, 2017). Strikingly, treatment with anti-
body 4D9 resulted in further elevation of microglial TREM2
expression (Fig 6B and C), whereas the total number of microglia
remained unchanged (Fig 6D). In contrast, the total number of cells
positive for P2RY12, a marker for homeostatic microglia (Butovsky
et al, 2014; Krasemann et al, 2017; Mazaheri et al, 2017), was selec-
tively decreased upon treatment with antibody 4D9 as compared to
the isotype control (Fig 6E and F). These findings therefore suggest
that 4D9 promotes the transition from homeostatic microglia to
DAM. Moreover, increased TREM2 and decreased P2RY12 expres-
sion was specifically observed in areas where microglia apparently
clustered around amyloid plaques (Fig 6B and E). Consistent with
this observation, we observed a reduced amyloid plaque load
throughout the cortex upon treatment with 4D9 (Fig 7A and B).
Higher magnification revealed that 4D9 treatment predominantly
caused a reduction in the fuzzy plaque halo (Fig 7C). Quantification
demonstrated that 4D9 treatment significantly reduced amyloid
plaque area and coverage within the cortex (Fig 7D and E). This
was further confirmed by Western blot analysis of soluble and insol-
uble Ab demonstrating that 4D9 treatment specifically results in a
reduction in soluble but not insoluble Ab (Fig 7F). Furthermore,
ELISA-mediated quantification of soluble and insoluble brain frac-
tions revealed a selective reduction in soluble Ab42 but not insol-
uble Ab42 (Fig 7G and H). Thus, our findings indicate that antibody
4D9 modulates beneficial microglial functions in vitro and in vivo.
Discussion
Neurodegenerative diseases are currently untreatable. We therefore
sought a new therapeutic strategy, with the goal to modulate micro-
glial function as a disease-modifying mechanism. Microgliosis is
observed in numerous neurological disorders, and only recently
evidence has been presented that TREM2-dependent microglial
functions appear to be protective in AD models (Ulland et al, 2017;
Focke et al, 2019; Parhizkar et al, 2019), AD patients (Ewers et al,
ª 2020 The Authors EMBO Molecular Medicine 12: e11227 | 2020 7 of 22
Kai Schlepckow et al EMBO Molecular Medicine
AB
C D E
Figure 4. 4D9 antibody promotes myelin and Ab(1–42) phagocytosis in primary microglia.
A Flow cytometry detection of cell-surface 4D9 (red) binding and isotype control (blue) on primary wild-type and Trem2/ mouse microglia. Data are shown as
mean fluorescent intensity (MFI).
B Uptake assay for fluorescently labeled myelin, Ab(1–42), and inactivated Escherichia coli particles. The top row shows that myelin and Ab (pseudocolored in white)
accumulate within the plasma membrane of primary microglia (labeled with DyLight 649 isolectin and pseudocolored in red). Overnight, pre-treatment with
antibody 4D9 significantly increased the percentage of substrate-positive cells (middle row). Pre-treatment with the isotope control did not affect the uptake rate
(bottom row). No changes in the uptake of E. coli particles were observed. Substrate uptake in the absence of antibody is shown in the top row. Hoechst 33342 was
used to counter stain the nuclei (in cyan) and to assess cell density. Scale bar = 20 lm.
C–E Quantification of the change in uptake of myelin (C), Ab(1–42) (D), and E. coli (E) upon antibody treatment relative to the uptake of the respective substrate in the
absence of antibody. The number of substrate-positive cells relative to the total number of cells was quantified in each condition. Data represent the mean  SEM
(n = 3). Two-way ANOVA (myelin), Sidak’s multiple comparisons test (time effect: F1,4 = 0.01123, P = 0.9207; treatment effect: F1,4 = 27.98, P = 0.0061; time x
treatment effect: F1,4 = 0.5948, P = 0.4836); P (1 h) = 0.1362; P (2 h) = 0.0185; unpaired t-test (two-tailed) with Welch’s correction (Ab(1–42) and E. coli);
P (Ab(1–42)) = 0.0151; P (E. coli) = 0.5751; n.s., not significant.
Data information: Statistical evaluations are displayed as follows: *P < 0.05.
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Figure 5. Pharmacokinetics and in vivo target engagement (TE) with 4D9 antibody.
A 4D9 demonstrates standard IgG pharmacokinetics in vivo. Peripheral clearance rates of 4D9 on a human IgG-effectorless backbone compared with an isotype control
were determined in wild-type mice by hIgG ELISA detection of plasma antibody concentrations 1 and 24 h, and 4 and 7 days after 10 mg/kg intravenous injection of
antibody.
B Brain antibody concentration was measured 24 h post-intravenous dosing of isotype hIgG at 100 mg/kg, and 4D9-hIgG dosed intravenously at 100, 50, and 10 mg/
kg. Detection of hIgG levels by ELISA demonstrated dose-dependent brain concentrations of 4D9 in the single digit nM range. Animals were perfused to minimize IgG
contribution from the plasma. Data represent the mean  SEM (n = 5).
C Schematic depicting the TE assay setup for bound and total sTREM2 detection. For the bound assay, a secondary anti-human IgG detects 4D9 antibody bound to
soluble TREM2 in CSF and plasma. For the total assay, a saturating amount of 4D9 antibody is added to eliminate unbound sTREM2. The ratio of 4D9-bound sTREM2
to total sTREM2 is calculated to determine the level of TE achieved by the concentration of antibody present.
D Target engagement time course demonstrated near 100% 4D9-bound sTREM2 in CSF of wild-type mice at 24 h post-dose. Over a 10-day time course with time
points at days 1, 2, 4, and 7 and study termination at day 10, the bound/total sTREM2 reduces gradually to reach ~ 50% by day 10. Animals were dosed intravenously
with 50 mg/kg of isotype and 4D9 antibodies. Data represent the mean  SEM (n = 5).
E Target engagement dose response demonstrated saturated bound sTREM2 at 50 and 10 mg/kg with > 50% bound sTREM2 at 1 mg/kg of antibody. 4D9-bound
sTREM2 was undetectable at 0.1 mg/kg and lower. 4D9 was IV-dosed at 50, 10, 1, 0.1, 0.01, 0.001, and 0.0001 mg/kg, and isotype-dosed at 50 mg/kg. CSF bound:
total sTREM2 in wild-type mice was measured at 24 h. Data represent the mean  SEM (n = 5).
F 4D9 antibody demonstrates a dose-dependent increase in total brain TREM2 levels. Quantification of total TREM2 in brain lysates from wild-type mice dosed with
4D9 or isotype control was performed by a MSD-platform-based ELISA. Data represent the mean  SEM (n = 5) and are shown as pg TREM2 per ug of total protein.
One-way ANOVA, Dunnett’s post hoc test, P (isotype vs 4D9 [100 mg/kg]) < 0.0001; P (isotype vs 4D9 [50 mg/kg]) = 0.0007.
Data information: Only male mice were used. Statistical evaluations are displayed as follows: ***P < 0.001; ****P < 0.0001.
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2019), and models of retinal degeneration (O’Koren et al, 2019).
TREM2 plays a central role in the switch of homeostatic to DAM
and seems to be acting as a central hub to regulate microglial func-
tion (Keren-Shaul et al, 2017; Krasemann et al, 2017; Ulrich et al,
2017). Based on evidence that full-length TREM2 on the cell surface
is signaling competent (Kleinberger et al, 2014), we hypothesized
that strategies that increase the amount of cell-surface TREM2 will
increase signaling and enhance TREM2-dependent microglial func-
tion. To do so, one could use known ADAM inhibitors or derivates
thereof to inhibit shedding of TREM2. However, ADAM10 has
numerous physiologically important substrates (Kuhn et al, 2016)
and additionally promotes Ab reduction as a non-amyloidogenic
protease (Haass & Selkoe, 1993). Thus, inhibition of ADAMs would
likely be counterproductive. We therefore investigated whether
selectively inhibiting TREM2 shedding with an antibody that hinders
ADAM10/17 from accessing the TREM2 cleavage site could increase
cell-surface full-length TREM2 and consequently stimulate TREM2-
dependent protective phenotypes that for example are reduced by
TREM2-associated risk variants. To do so, we screened monoclonal
antibodies directed against the entire ectodomain of TREM2 for their
ability to bind epitopes within the stalk region, which contains the
cleavage site. We identified antibody 4D9, which binds the stalk
region in the immediate vicinity of the ADAM10/17 cleavage site
and demonstrated increased cell-surface full-length TREM2, and
reduced ADAM10/17-mediated TREM2 shedding. Moreover, the
4D9 antibody concomitantly activated SYK signaling, as detected by
phosphorylation of SYK, and enhanced survival of macrophages
in vitro after growth factor withdrawal, strongly suggesting that
indeed full-length, cell-surface TREM2 receptor exerts cell-autono-
mous signaling functions. Additional evidence for the signaling
capacity of full-length TREM2 comes from the analysis of the AD-
associated p.TREM2 H157Y variant (Jiang et al, 2016) which
increases shedding of TREM2 and concomitantly reduces TREM2-
dependent phagocytosis (Schlepckow et al, 2017), thus furthermore
indicating that the amount of cell-surface TREM2 correlates with
microglial activity. This is also consistent with our previous finding
demonstrating that inhibition of ADAM proteases is sufficient to
increase TREM2-dependent phagocytosis (Kleinberger et al, 2014).
Similar findings regarding antibody-mediated survival of macro-
phages were reported by Cheng et al (2018), although the mecha-
nism of action and in vivo activity of this antibody was not
investigated. We now demonstrate that 4D9 exerts its modulating
activity via dual mechanisms, first by prevention of shedding and
second by agonistic activation of TREM2 receptor signaling. Both
mechanisms were found to require bivalent binding in cell-based
studies, indicating that cross-linking of cell-surface TREM2 via a
stalk epitope underlies antibody mechanism of action. Furthermore,
we also provide evidence for in vivo TE and modulation of TREM2
◀ Figure 6. 4D9 antibody modulates TREM2 functions within the brain.A Schematic outlining study design and timeline of intraperitoneal injections of either isotype control of 4D9 antibody in 6-month-old APP-NL-G-F and age-matched
WT mice.
B Immunohistochemical costainings of TREM2 (magenta) and IBA1 (green) microglia in the cortex of isotype control and 4D9-injected WT and APP-NL-G-F mice. Side
panel shows images from each staining at a larger magnification indicated by the dotted white boxes. Scale bar = 10 lm; scale bar (inset) = 2.5 lm.
C Quantification of cortical TREM2 stainings shown in (B). Two-way ANOVA, Tukey’s multiple comparison test (genotype effect: F1,23 = 70.63, P ≤ 0.0001; treatment
effect: F1,23 = 14.33, P = 0.0010; genotype × treatment effect: F1,23 = 14.51, P = 0.0009); P (WT isotype vs WT 4D9) > 0.9999; P (WT isotype vs APP isotype) = 0.02;
P (WT 4D9 vs APP 4D9) < 0.0001; P (APP isotype vs APP 4D9) = 0.0001; n.s., not significant.
D Quantification of cortical IBA1 staining shown in B. Two-way ANOVA, Tukey’s multiple comparison test (genotype effect: F1,21 = 215.4, P ≤ 0.0001; treatment effect:
F1,21 = 0.5994, P = 0.4475; genotype × treatment effect: F1,21 = 0.2992, P = 0.5902); P (WT isotype vs APP isotype) < 0.0001; P (WT 4D9 vs APP 4D9) < 0.0001; P (APP
isotype vs APP 4D9) = 0.9986; n.s., not significant.
E Confocal images of P2RY12 (red), IBA1 (green), and Ab (gray) costainings from cortex. Top panel: Dotted white boxes indicate the areas in P2RY12 and IBA1 costainings
that are magnified as inset. Bottom panel: Insets show P2RY12, IBA1, and Ab costainings at a larger magnification. Of note, we did not observe a complete co-
localization of P2RY12 and IBA1 suggesting different microglial populations. Scale bar = 10 lm; scale bar (insets) = 5 lm.
F Quantification of P2RY12-stained cells in the cortex shown in (E). Two-way ANOVA, Tukey’s multiple comparison test (genotype effect: F1,23 = 71.99, P ≤ 0.0001;
treatment effect: F1,23 = 9.029, P = 0.0063; genotype × treatment effect: F1,23 = 5.93, P = 0.0231); P (WT isotype vs APP isotype) = 0.0018; P (WT 4D9 vs APP
4D9) < 0.0001; P (APP isotype vs APP 4D9) = 0.0051.
Data information: Each data point for all quantifications represents an average of n = 3 replicates per mouse. All data represent the mean  SEM (n = 6–7). No gender-
specific differences could be observed. Statistical evaluations are displayed as follows: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
▸◀ Figure 7. 4D9 antibody reduces plaque burden.A, B Overview of the cortex immunohistochemically stained for Ab plaques in 6-month-old APP-NL-G-F mice treated with isotype control (A) and 4D9 antibody (B).
Scale bar = 100 lm.
C Higher magnification images of cortical Ab plaques in APP isotype and 4D9-injected mice. Scale bar = 10 lm.
D Quantification of cortical plaque area from stainings shown in (C). Mann–Whitney U-test, P = 0.0082.
E Quantification of total plaque coverage of Ab stainings in the cortex shown in (C). Mann–Whitney U-test, P = 0.014.
F Immunoblot analysis of soluble (DEA fraction, top) and insoluble Ab levels (FA fraction, bottom) in brains of APP-NL-G-F mice treated with either isotype control or
4D9 antibody. While a reduction in levels of soluble Ab is evident from the DEA fractions, no change in levels of insoluble Ab could be detected in the FA fractions.
Note that the higher background in the DEA immunoblot is due to a much longer exposure time, which was needed to visualize soluble Ab.
G MSD ELISA quantification of soluble Ab42 in DEA extracts as shown in (F). Mann–Whitney U-test, P = 0.026.
H MSD ELISA quantification of insoluble Ab42 in FA extracts as shown in (F). Unpaired t-test (two-tailed) with Welch’s correction; P = 0.0877.
Data information: Each data point for both quantifications represents an average of n = 3 replicates per mouse. All data represent the mean  SEM (n = 6–7). No
gender-specific differences could be observed. Statistical evaluations are displayed as follows: *P < 0.05; **P < 0.01.
Source data are available online for this figure.
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function. In vivo TE was successfully demonstrated by near-
complete coverage of 4D9-bound sTREM2 in CSF and increased
total TREM2 in brain of 4D9-treated mice. Furthermore, increased
microglial TREM2 and decreased P2RY12 expression also supports
the immunomodulatory mode of action of 4D9 and suggests that
this dual function antibody promotes a shift from homeostasis to a
DAM state. This is in line with our observation that antibody 4D9
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4D9 appears to selectively reduce soluble Ab associated with the
plaque halo, one may even argue that antibody treatment reduces
the amount of toxic Ab oligomers liberated by amyloid plaques.
Reduction in amyloid plaque pathology occurred after a surpris-
ingly short 10-day treatment, which may be related to the diffuse
nature of amyloid plaques in this model (preprint: Monasor et al,
2019). However, we currently do not know the fate of engulfed Ab.
Additional data will also be required to demonstrate that antibodies
with properties similar to 4D9 can be used to modulate microglial
function for the treatment of AD or other indications. In that
regard, it is currently unclear whether sTREM2 itself may have
essential functions in either a cell-autonomous manner or a non-
cell-autonomous manner (Ulland et al, 2017; Zhong et al, 2017,
2019). Moreover, although a loss of function as caused by certain
risk variants of TREM2 disables microglia, relegating them to a
homeostatic state (Mazaheri et al, 2017), absence of progranulin
(PGRN) has the opposite consequence, namely arresting microglia
in a disease-associated state (Gotzl et al, 2019). Strikingly,
both opposite phenotypes are deleterious to brain health, and
absence of either TREM2 or PGRN causes similar brain-wide distur-
bances in energy metabolism as measured by FDG-PET (Gotzl et al,
2019).
Careful investigation of how Trem2 activity over time correlates
with microglial function and additional data elucidating the impact
of TREM2 antibody immunomodulatory activity on microglia
in vivo will further improve our understanding of the chronic effects
of enhanced TREM2 function and potential for efficacy in the clinic.
Although TE in brain is possible with 4D9 at early time points, high-
dose levels are required to maintain this effect, suggesting TREM2-
enhancing antibodies would benefit from blood–brain barrier pene-
trating technology to improve brain exposure (Yu et al, 2011;
Niewoehner et al, 2014). Finally, any TREM2-based therapeutic
strategy must take peripheral immune cells into account, since they
also express TREM2 and may thus be modulated. In fact, recent
work demonstrated TREM2-dependent protective functions in lipid-
associated peripheral macrophages, showing effects on lipid uptake
and metabolism that are important for the prevention of adipocyte
hypertrophy under conditions of a high-fat diet (Jaitin et al, 2019).
Strikingly, such protective functions by lipid-associated macro-
phages may also be boosted by TREM2 function enhancing antibod-
ies.
Although a number of questions remain to be answered, our data
suggest that TREM2-modulating approaches can impact disease-
relevant microglial functions. Studies from multiple groups have
recently improved our understanding of microglial function in
disease and how it is impacted by genetic risk factors. Notably, lipid
metabolism, storage, and processing has emerged as a potentially
important contributor to proper microglial function in the CNS
(Chan et al, 2012; Wang et al, 2015; Keren-Shaul et al, 2017;
Griciuc et al, 2019; Marschallinger et al, 2020; Nugent et al, 2019).
This may indicate that TREM2-stimulating therapeutic approaches
could be employed in a variety of different clinical syndromes
including AD, frontotemporal lobar degeneration, amyotrophic
lateral sclerosis, retinal degeneration, multiple sclerosis, and
obesity-associated metabolic syndromes. Furthermore, our earlier
findings that antibody-mediated amyloid plaque clearance is
TREM2-dependent (Xiang et al, 2016) open the opportunity of a
combinatorial treatment using anti-Ab antibodies together with
microglia stimulating antibodies such as 4D9. This may be specifi-
cally of interest in light of the recent findings that a clinical trial
using the anti-Ab antibody aducanumab, though controversial,
suggests that treatment may slow clinical decline of patients at the
highest dose of the drug. A combinatorial treatment strategy may
therefore boost amyloid clearance via enhancement of TREM2-
dependent microglial activity and thus enable lower dosing of the
anti-Ab antibody.
Materials and Methods
Generation of antibodies specific for mouse TREM2
Eight-month-old female Wistar rats were immunized subcuta-
neously (s.c.) and intraperitoneally (i.p.) with a mixture of 70 lg
recombinant his-tagged mouse Trem2 protein (aa19–171, Creative
BioMart) in 500 ll PBS, 5 nmol CpG2006 (TIB MOLBIOL, Berlin,
Germany), and 500 ll Incomplete Freund’s adjuvant. After 6 weeks,
a boost without Freund’s adjuvant was given i.p. and s.c. 3 days
before fusion. Fusion of the myeloma cell line P3X63-Ag8.653 with
the rat immune spleen cells was performed using polyethylene
glycol 1500 according to standard procedure (Kohler & Milstein,
1975). After fusion, the cells were plated in 96-well plates using
RPMI 1640 with 20% fetal calf serum, penicillin/streptomycin,
glutamine, pyruvate, and non-essential amino acids supplemented
with HAT Hybri-Max medium supplement (Sigma). Hybridoma
supernatants were tested in an enzyme-linked immunoassay using
His-tagged mouse TREM2 protein. After blocking with PBS/2% FCS,
hybridoma supernatants were added for 30 min. After one wash
with PBS, bound antibodies were detected with a cocktail of HRP-
conjugated mAbs against the four rat IgG isotypes. HRP was visual-
ized with ready-to-use TMB substrate (1-StepTM Ultra TMB-ELISA,
Thermo). The hybridoma cells of TREM2-reactive supernatants were
cloned at least twice by limiting dilution. The IgG subclass was
determined in an ELISA with mouse anti-rat kappa light chain anti-
bodies as capture and HRP-coupled mouse anti-rat IgG subclass-
specific antibodies for detection.
Hybridoma antibody sequencing
Total RNA was extracted from the monoclonal antibody-expres-
sing hybridoma cells using Qiagen RNeasy Plus Mini Kit (Qiagen,
Germantown, MD) following manufacturer’s instructions. The
extracted total RNA was used as template for 50-RACE-ready
cDNA synthesis (Takara Bio, Mountain View, CA). The heavy
chain variable domain (VH) and the light chain variable domain
(VK) of 4D9 were amplified separately by PCR using the 50-RACE
adaptor-specific forward primer, rat IgG, or kappa constant-
specific reverse primers (Bradbury, 2010). For VK domain amplifi-
cation, a peptide nucleic acid oligo (CCTGTGGAGGAGGAG-
GATGCT-KK) was used to selectively amplify the functional kappa
chain (Cochet et al, 1999). The PCR products of VH and VK were
purified and cloned into the pCR-TOPO vector (Invitrogen, Carls-
bad, CA). The cloned vector was transformed into TOP10 E. coli
(Invitrogen, Carlsbad, CA) by chemical transformation and
selected on a LB agar plate containing 100 lg/ml carbenicillin.
Sanger sequencing was done on bacteria colonies using the M13
ª 2020 The Authors EMBO Molecular Medicine 12: e11227 | 2020 13 of 22
Kai Schlepckow et al EMBO Molecular Medicine
forward and M13 reverse primers to sequence VH and VK of the
4D9 antibody.
Generation of recombinant anti-TREM2 antibodies
Effectorless IgG
The polypeptide sequences of VH and VK were codon-optimized
for CHO cell expression and synthesized by Integrated DNA Tech-
nologies (Coralville, IA). The synthesized VH and VK fragments
were cloned into the human IgG1 containing effector knockout
mutations (L234A, L235A, and P329G) and human kappa chain
expression vectors, respectively. ExpiCHO cells (Gibco, Carlsbad,
CA) were transfected with the antibody expression plasmids. The
culture medium containing the expressed recombinant antibody
was harvested 5 days after transfection. The recombinant antibody
was purified by MabSelect SuRe (GE Life Sciences, Pittsburgh,
PA). The purity of 4D9 recombinant antibody was analyzed by
SDS–PAGE (NuPAGE 4–12% Bis–Tris, Invitrogen, Carlsbad, CA)
and size exclusion chromatography (Tosoh TSKgel, Tosoh Bios-
ciences, Japan).
Fab fragment
To generate a monovalent 4D9 Fab antibody fragment, the heavy
chain expression vector was modified to include only the VH-CH1
domains as a Fab-heavy chain expression vector. ExpiCHO cells
(Gibco, Carlsbad, CA) were transfected with the antibody expres-
sion plasmids. The culture medium containing the expressed
recombinant antibody or Fab antibody fragment was harvested
5 days after transfection. The recombinant mouse–human chimeric
IgG antibody was purified by MabSelect SuRe (GE Life Sciences,
Pittsburgh, PA). The recombinant Fab antibody fragment was
purified by KappaSelect (GE Life Sciences). The purity of 4D9
recombinant antibody and Fab antibody fragments was analyzed
by SDS–PAGE (NuPAGE 4–12% Bis–Tris, Invitrogen, Carlsbad,
CA) and size exclusion chromatography (Tosoh TSKgel, Tosoh
Biosciences, Japan).
Epitope mapping of antibody 4D9
Biotinylated polypeptides of the full-length mouse Trem2 stalk
(extracellular domain [ECD] amino acids 131–169: CDPLDDQDAGD
LWVPEESSSFEGAQVEHSTSRNQETSFPP), tiled stalk regions of the
mouse TREM2 (DPLDDQDAG, DDQDAGDLW, DAGDLWVPE,
DLWVPEESS, VPEESSSFE, ESSSFEGAQ, SFEGAQVEH, GAQVEHSTS,
VEHSTSRNQ, STSRNQETS, RNQETSFPP), and a truncated cleavage
site peptide (149–163, CSFEGAQVEHSTSRNQ) were purchased from
Elim Biopharmaceuticals, Inc. (Hayward, California, USA). N-term-
inal cysteine was added to both full-length and truncated stalk
peptides to enable maleimide–thiol conjugation of biotin. The
lyophilized biotinylated peptides were reconstituted in 20 mM Tris
buffer at pH 8.0. Antibody binding to TREM2 stalk peptides was
detected using a sandwich ELISA. Briefly, a 96-well half-area ELISA
plate was coated with streptavidin overnight at 4°C. The following
day, biotinylated TREM2 stalk peptides diluted in 1% BSA/PBS
were added to the plate and incubated for 1 h. Antibodies diluted in
1% BSA/PBS were then added and incubated for 1 h. Antibodies
bound to peptide were detected with anti-Human Kappa-HRP
secondary antibody diluted in 1% BSA/PBS. Plates were developed
with the addition of TMB substrate and stopped by the addition of
2N sulfuric acid.
Competition peptide ELISA
Antibody binding to the TREM2 stalk peptide (DPLDDQDAGDLWV-
PEESSSFEGAQVEHSTSRNQETSFPP-Biotin) was detected using a
competitive binding ELISA format assay. A 96-well half-area ELISA
plate (Corning Costar #3690) was coated with murine TREM2 His-
tagged protein overnight at 4°C. The plate was blocked with a 3%
BSA/TBST solution and incubated for 2 h at room temperature. Anti-
TREM2 antibody was pre-incubated with a serial dilution of murine
TREM2 stalk peptide for 1 h. After blocking, the pre-incubated anti-
body and peptide sample was added to the plate and incubated for an
additional hour. Antibodies bound to murine TREM2 His-tagged
protein were detected with anti-human kappa-HRP secondary anti-
body diluted in 3% BSA/TBST. Plates were developed with the addi-
tion of TMB substrate and stopped by the addition of 2N sulfuric acid.
cDNA constructs
gBlock gene fragments (Integrated DNA Technologies) coding for
DAP12-P2A-TREM2 were cloned into the pcDNA5/FRT/TO
vector. The coding sequence of murine wild-type DAP12 included a
C-terminal V5-epitope tag (50-GGTAAGCCTATCCCTAACCCTCTC
CTCGGTCTCGATTCTACG-30; aa sequence: GKPIPNPLLGLDST),
and the murine wild-type TREM2 sequence included an N-terminal
HA-epitope tag (50-TACCCATACGATGTTCCAGATTACGCT-30; aa
sequence: YPYDVPDYA). The HA-epitope tag was inserted directly
after the sequence of the endogenous TREM2 signal peptide (aa1–
18). The coding sequences of DAP12 and TREM2 are separated by
the P2A sequence (GGAAGCGGAGCTACTAACTTTAGCTTGTTGAA
ACAGGCTGGGGATGTAGAGGAAAACCCTGGCCCA) (Kim et al, 2011).
In vitro TREM2 peptide cleavage detection by
fluorescence polarization
TREM2 full length “long” stalk and truncated cleavage site “short”
stalk peptide were fluorophore-labeled via addition of a lysine
residue to the C-terminal end of the TREM2 stalk peptides (se-
quences under “Epitope mapping of antibody 4D9”) in order to
enable conjugation of 5-Carboxyfluorescein. The peptide synthesis,
conjugation, and purification was performed by Elim Biopharma-
ceuticals, Inc. (Hayward, CA, United States). FAM-conjugated short-
and long-stalk region mouse TREM2 peptides were prepared in
assay buffer (25 mM Tris pH 7.5, 2.5 lM ZnCl2, 0.005% Brij-35)
with streptavidin. TREM2 antibodies were then pre-incubated with
TREM2 stalk peptides for 30 min at RT. After pre-incubation,
ADAM17 was added and incubated with peptides for 20 h at 37°C.
The following day, samples were further diluted in assay buffer and
transferred to a black opaque 384-well plate. Fluorescence polariza-
tion of peptides was subsequently measured on Perkin Elmer EnVi-
sion plate reader.
HEK293 cell culture and generation of isogenic cell lines
Flp-InTM 293 cells (HEK293 Flp-In; Life Technologies) were cultured
in Dulbecco’s modified Eagle’s medium (DMEM) with GlutaMAX I,
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supplemented with 10% (v/v) fetal calf serum (FCS), and 200 lg/
ml Zeocin and penicillin/streptomycin (PAA Laboratories, Pasching,
Austria). Transfections of cDNA constructs were carried out using
Lipofectamine 2000 reagent according to the manufacturer’s recom-
mendations. For stable overexpression of Dap12-P2A-Trem2 cDNA
constructs, HEK293 Flp-In cells were co-transfected with pOG44
(Flp-recombinase expression vector; Life Technologies) and selected
using 200 lg/ml hygromycin B. Pools of isogenic cells were used
for all experiments.
Cell culture of bone marrow-derived macrophages
BMDMs were cultured as described before (Xiang et al, 2016; Klein-
berger et al, 2017). For immunoblot analyses, BMDMs were
harvested after 7 days, while for all other experiments BMDMs were
harvested after 5 days.
Isolation and culturing of primary microglia for FACS analysis of
4D9 binding
Primary mouse microglia were obtained from mixed glial culture.
Briefly, cerebral cortices were isolated from postnatal day 2 C57BL/
6 mice obtained from Charles River Laboratories International, Inc.
(Davis, CA). Tissues were minced and incubated in 0.25% trypsin-
EDTA, mechanically triturated in DMEM/F-12 with 10% FBS, and
plated on poly-L-lysine-coated 75-ml flasks. Cultures were main-
tained for 14 days with media changes every 4 days. Microglial cells
were isolated by shaking flasks at 200 rpm in a Lab-LineTM Incubator
Shaker for 4 h.
Antibody treatments, sample preparation, and immunoblotting
HEK293 Flp-In cells stably overexpressing murine Dap12-P2A-
Trem2 cDNA constructs were seeded on poly-L-lysine (10 lg/ml)-
coated six-well plates at a density of 1.5 × 105/cm2 and grown for
24 h. Medium was changed to complete culture medium (DMEM,
10% FCS, Pen/Strep) containing 20 lg/ml TREM2 antibodies and
incubated for 18–20 h. As control for blocking of Trem2 shedding,
cells were treated with GM6001, a broadband ADAM inhibitor
(25 lM, Enzo Life Sciences) or DMSO as a vehicle control. Condi-
tioned medium was collected, immediately cooled down on ice,
centrifuged at 16,840 g for 20 min at 4°C to remove cellular debris,
and supernatants were frozen at 20°C until analysis. To prepare
membrane fractions, cells were washed twice with ice-cold PBS,
resuspended in ice-cold hypotonic buffer (0.01 M Tris, pH 7; 1 mM
EDTA; 1 mM EGTA) freshly supplemented with protease inhibitor
(Sigma), and incubated on ice for 30 min. After snap freezing in
liquid nitrogen and thawing, the disrupted cells were centrifuged at
16,090 g for 45 min at 4°C. The resulting pellet was resuspended in
STE lysis buffer (150 mM NaCl, 50 mM Tris–HCl, pH 7.6, 2 mM
EDTA, 1% Triton X-100), incubated for 20 min on ice, and clarified
by centrifugation at 16,090 g for 30 min at 4°C. Protein concentra-
tions were measured using the BCA method, and equal amounts of
protein were mixed with Laemmli sample buffer supplemented with
beta mercaptoethanol. Proteins were then separated by SDS–PAGE
and transferred onto polyvinylidene difluoride membranes (Hybond
P; Amersham Biosciences, Aylesbury, UK). Bound antibodies were
visualized by corresponding HRP-conjugated secondary antibodies
using enhanced chemiluminescence technique (Pierce). BMDMs
were seeded at a density of 1.3 × 105/cm2 in six-well plates, and the
medium was supplemented with either 4D9 or isotype control anti-
body at 20 lg/ml. Conditioned media and cells were collected and
processed as described above for HEK293 Flp-In cells after overnight
incubation.
Specificity of antibody 4D9 for mouse TREM2 was demonstrated
by immunoblotting of 10 ng mouse TREM2-(His)6 as purchased
from Sino Biological. For immunoblotting of 10 ng human TREM2-
(His)6 (Sino Biological) and 10 ng mouse TREM1-Fc (R&D Systems),
AF1828 and AF1187 antibodies (both R&D Systems) were used,
respectively. A complete list of all antibodies used is shown in
Table EV1.
ELISA-based quantification of TREM2 protein species
In vitro cell culture
To quantify the levels of sTREM2 and membrane-bound TREM2
upon treatment with anti-TREM2 antibodies, an electrochemilumi-
nescence-based assay using the Meso Scale Discovery Platform was
established. Streptavidin-coated 96-well plates were blocked over-
night at 4°C in blocking buffer (3% bovine serum albumin [BSA]
and 0.05% Tween 20 in PBS, pH 7.4). Plates were incubated for 1 h
at RT with 0.125 lg/ml biotinylated polyclonal sheep anti-TREM2
capture antibody (BAF1729; R&D Systems) diluted in blocking buffer
followed by washing two times with washing buffer (0.05% Tween
20 in PBS, pH 7.4) using a plate washer. Samples were mixed 9:1
with denaturation buffer (200 mM Tris–HCl pH 6.8, 4% (w/v) SDS,
40% (v/v) glycerol, 2% (v/v) b-mercaptoethanol, 50 mM EDTA)
and boiled at 95°C for 5 min to dissociate TREM2 antibodies from
either sTREM2 or membrane-bound TREM2. In the following, plates
were incubated at RT for 2 h with the respective samples diluted in
sample buffer (1% BSA and 0.05% Tween 20 in PBS, pH 7.4). For
quantification of sTREM2, samples were diluted 1:20 and 1:2 for
HEK293 Flp-In cells and BMDM, respectively. For quantification of
membrane-bound TREM2, 1.5 lg and 1.9 lg from membrane frac-
tions of HEK293 Flp-In cells and BMDM, respectively, were
employed. Plates were washed two times with washing buffer before
incubation for 1 h at RT with 1 lg/ml rat monoclonal anti-TREM2
antibody (clone 5F4 (Xiang et al, 2016)) diluted in blocking buffer.
After two additional washing steps, plates were incubated with a
SULFO-TAG-labeled anti-rat secondary antibody (1:1,000; Meso
Scale Discovery) diluted in blocking buffer and incubated for 1 h at
RT. Lastly, plates were washed two times with washing buffer and
two times with PBS followed by adding 1× Meso Scale Discovery
Read buffer. The light emission at 620 nm after electrochemical
stimulation was measured using the Meso Scale Discovery Sector
Imager 2400 reader (MSD). Concentrations of sTREM2 and
membrane-bound TREM2 were finally calculated using the MSD
Discovery Workbench software (v4.0.12). As a standard, we used
recombinant murine TREM2 (Ho¨lzel Diagnostika). For standard
curve determination, twofold serial dilutions were performed in
either sample dilution buffer (sTREM2) or the lysis buffer as used
for preparation of membrane fractions (membrane-bound TREM2)
supplemented with protease inhibitor mix (Sigma) on the plate
spanning concentrations from 4,000 to 62.5 pg/ml. Standard
samples underwent the same denaturation procedure as the samples
collected from HEK293 Flp-In cells and BMDM. In all incubation
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steps at RT, the plate was usually shaken at 300 rpm. All plate
washings were performed using a plate washer (ELx405, BioTek).
In vivo
Mouse brains were perfused with cold PBS, and cortex and hippocam-
pus were sub-dissected out of whole brain tissue and weighed to
match tissue mass for each animal. Brain lysate was generated using
lysis buffer (Cell Signaling #9803) containing protease inhibitor cock-
tail (Roche #4693159001) and PhosSTOP (Roche #4906837001) each
added into the sample tube (1 ml lysis buffer for 100 mg tissue).
Subsequently, one 3-mm stainless steel bead (Qiagen) was added into
each tube and samples were homogenized with the Qiagen Tissue-
Lyser II at 28 Hz for 3 min. The homogenization step was repeated 3
times. The homogenized samples were then incubated on ice for
10 min followed by centrifugation at 18,660 g for 20 min at 4°. Super-
natants were transferred to new tubes and stored at 80° for follow-
ing protein concentration determination.
To quantify total brain TREM2 levels, an electrochemilumines-
cence-based assay using the Meso Scale Discovery Platform was
utilized. Streptavidin-coated 96-well plates were blocked using
blocking buffer (25% MSD Blocker A and 75% TBST) for 1 h at
R.T. Plates were then incubated for 1 h at RT with 1 lg/ml biotiny-
lated polyclonal sheep anti-TREM2 capture antibody (BAF1729;
R&D Systems) diluted in blocking buffer followed by washing three
times with washing buffer (0.05% Tween 20 in TBS) using a plate
washer. Brain lysates were diluted in blocking buffer (1:5) and
aliquoted on MSD-compatible plates. All plates were incubated at
RT for 1 h. Plates were washed three times with washing buffer on
a ELx406 plate washer (BioTek) before incubation for 1 h at
RT with 10 lg/ml monoclonal anti-TREM2 antibody (clone 4D9)
diluted in blocking buffer. Plates were shaken at 800 rpm in all
incubation steps.
After three additional washing steps, the MSD plates were incu-
bated with SULFO-TAG-labeled anti-human secondary antibody
(1 lg/ml; Meso Scale Discovery) diluted in blocking buffer and
incubated for 1 h at RT. Lastly, plates were washed three times with
washing buffer followed by adding 2× Meso Scale Discovery Read
buffer. The light emission at 620 nm after electrochemical stimula-
tion was measured using the Meso Scale Discovery Sector Imager
S600 reader (MSD). Concentrations of TREM2 were calculated using
the MSD Discovery Workbench software. Recombinant murine
extracellular domain TREM2 protein was used to generate a stan-
dard curve. For standard curve determination, fourfold serial dilu-
tions were performed in lysis buffer as used for preparation of brain
lysates supplemented with protease inhibitor mix (Sigma) on the
plate with concentrations ranging from 62.5 ng/ml to 15.25 pg/ml.
Data are normalized per ug total protein.
Dose-dependent sTREM2 shedding assay
HEK-293F cells stably overexpressing mouse TREM2 were plated at
50,000 cells per well in complete media (DMEM supplemented with
GlutaMAX, 10% FBS, 1% Pen Strep) in PDL-coated plates and incu-
bated for 24 h at 37°C. The following day, media were removed and
cells were washed once with Opti-MEM and treated with a dose
titration of 4D9 antibody diluted in Opti-MEM and incubated for
18 h at 37°C. After incubation, supernatants were harvested for
detection of shed mouse sTREM2 in cell culture supernatant.
To quantify the levels of sTREM2 upon treatment with anti-
TREM2 antibodies, an electrochemiluminescence-based assay using
the Meso Scale Discovery Platform was established. Streptavidin-
coated 96-well plates were incubated for 2 h at RT with 1 lg/ml
biotinylated polyclonal sheep anti-TREM2 capture antibody
(BAF1729; R&D Systems) diluted in PBS (pH 7.4). After washing
two times with washing buffer (0.05% Tween 20 in TBS, pH 7.4)
using a plate washer, plates were blocked for 1 h at RT in blocking
buffer (3% BSA and 0.05% Tween 20 in TBS, pH 7.4). Samples
were mixed 13:7 with denaturation buffer (1× NuPAGE Sample
Reducing Agent, 1× NuPAGE LDS Sample Buffer) and boiled at 95°C
for 5 min to dissociate TREM2 antibodies from either sTREM2 or
membrane-bound TREM2. In the following, plates were incubated
at RT for 2 h with the respective samples diluted 1:10 in blocking
buffer (3% BSA and 0.05% Tween 20 in TBS, pH 7.4). Plates were
washed two times with washing buffer before incubation for 1 h at
RT with sulfo-tagged polyclonal sheep anti-TREM2 (AF1729; R&D
Systems) diluted 1:5,000 in blocking buffer. Lastly, plates were
washed two times with washing buffer and followed by the addition
of 2× Meso Scale Discovery Read buffer. The light emission at
620 nm after electrochemical stimulation was measured using the
Meso Scale Discovery Sector Imager 2400 reader (MSD). Concentra-
tions of sTREM2 were finally calculated using the MSD Discovery
Workbench software (v4.0.12). As a standard, we used recombinant
murine TREM2 (Ho¨lzel Diagnostika). For standard curve determina-
tion, half-log-fold serial dilutions were performed in sample dilution
buffer (sTREM2) on the plate spanning concentrations from 4,000 to
62.5 pg/ml. Standard samples did not undergo denaturation proce-
dure prior to incubation on the plate. In all incubation steps at RT,
the plate was usually shaken at 600 rpm. All plate washings were
performed using a plate washer (ELx405, BioTek).
FACS for cell-surface 4D9 binding to mouse TREM2
For mouse TREM2 surface staining, BMDM and mouse microglial
cells were harvested, pelleted, resuspended in FACS buffer
(PBS + 0.5% BSA + FcX solution 5 ll/ml) at 106/ml, and seeded at
100,000 cells per well in a 96-well round bottom. Cells were centri-
fuged, and biotinylated-4D9 and isotype control were added at
200 nM and incubated for 45 min on ice. Cells were centrifuged and
washed with FACS buffer for three times. Cells were then incubated
with secondary antibody (APC Streptavidin 1:300, BD Pharmingen
#554067) for 30 min on ice. After incubation, cells were washed
with FACS buffer three times and resuspended in 100 ll of FACS
buffer, and then analyzed by flow cytometry (BD FACSCanto II).
Antibody binding kinetics
Human TREM2, mouse TREM2, and mouse TREM1 ECD binding
affinities to 4D9 were determined by SPR using a Biacore 8K instru-
ment. Biacore Series S CM5 sensor chip was immobilized with a
mixture of two monoclonal mouse anti-Fab antibodies (Human Fab
Capture Kit from GE Healthcare). Serial twofold dilutions of recom-
binant mouse Trem2 were injected at a flow rate of 30 ll/min for
300 s followed by 1,200-s dissociation in HBS-EP+ running buffer
(GE, #BR100669). Binding response was corrected by subtracting
the RU from a blank flow cell. A 1:1 Langmuir model of simultane-
ous fitting of kon and koff was used for kinetics analysis.
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Immunocytochemistry of HEK293 cells
HEK Flp-In cells stably overexpressing either empty vector or
mouse TREM2/DAP12 were seeded on coverslips coated with poly-
L-lysine (10 lg/ml). After incubation at 37°C and 5% CO2 for 24–
48 h, media were removed and cells were washed three times for
5 min with PBS. Cells were incubated with freshly prepared fixa-
tion solution (4% (w/v) paraformaldehyde, 4% sucrose in PBS pH
7.4) for 10 min and washed three times for 5 min with PBS. Upon
quenching the autofluorescence for 15 min at RT using 50 mM
NH4Cl in PBS, cells were again washed three times for 5 min with
PBS. In the following, cells were blocked with 5% BSA in PBS
overnight at 4°C. Cells were then incubated for 2 h at 37°C with
either antibody 4D9 (0.4 lg/ml) or an anti-HA antibody (clone
3F10; Roche; 1 lg/ml) diluted in 0.5% BSA in PBS. After incuba-
tion with the primary antibody, cells were washed three times for
5 min with PBS. Goat anti-rat Alexa 488 secondary antibody
(Thermo Fisher Scientific; #11006; 1:500) was added, and cells
were incubated for 1 h at 37°C followed by three washes with PBS
for 5 min. Cells were then counter-stained with DAPI (1:5,000 in
PBS) and washed another three times for 5 min at 37°C. Finally,
coverslips were mounted using Fluoromount Aqueous Mounting
Medium (F4680, Sigma). Confocal images were acquired using a
LSM 800 confocal microscope (Zeiss) and the ZEN 2.5 Zeiss soft-
ware package. Two–three images were taken per condition using a
63× oil differential interference contrast objective (1.40 Oil DIC
M27) at 1,437 × 1,437 pixel resolution with a z-step size of usually
0.7 lm at 4 lm thickness. Image analysis was subsequently done
using the FIJI software package (ImageJ). Briefly, channels and
focal planes were split followed by background subtraction using a
sliding paraboloid (rolling ball radius of 50 pixel) on the focal
plane of interest. Brightness and contrast were then adjusted such
as to optimize the balance between TREM2 surface and DAPI
stainings. Finally, channels were merged again to generate images
as shown in Fig 1D. Preparation of coverslips was conducted using
sterile filtered buffers.
p-SYK AlphaLISA
HEK293 Flp-In cells overexpressing mouse TREM2 and mouse
DAP12 were plated in complete media (1× DMEM, 1× GlutaMAX,
10% FBS, 1% Pen Strep) at 50,000 cells/well in PLL-coated 96-
well plates. Cells were incubated overnight at 37°C in a cell culture
incubator. The following morning, plates were washed 3× with
HBSS and 50 ll of liposome/antibody mixture or liposome alone
diluted in HBSS was added to each well. Antibodies and liposomes
were employed at 20 lg/ml and 1 mg/ml, respectively. Cells were
incubated for 5 min at 37°C before treatment solutions were
removed from the plate by gentle pipetting. Cells were quickly
lysed with 40 ll lysis buffer supplemented with protease inhibitor
mix (Sigma) and phosphatase inhibitor (PhosSTOP, Roche) and
incubated on ice for 30 min. Phosphorylated SYK (p-SYK) was
measured in cell lysates using an AlphaLISA SureFire Ultra p-SYK
Assay Kit (Tyr525/526; PerkinElmer), and plates were read on an
EnSpire Multimode Plate Reader (PerkinElmer). To evaluate effects
of antibody 4D9 alone on p-SYK levels, the experiment was carried
out identically with the exception that washing steps employing
HBSS were omitted.
Preparation of liposomes
POPC/POPS (7:3) liposomes at 10 mg/ml were prepared as follows:
7 mg POPC and 3 mg POPS were dissolved in chloroform followed
by thorough evaporation of solvent. The lipid mixture was then
resuspended in 1 ml HBSS, and suspensions were extruded using
100 nm polycarbonate membranes (Whatman, article no. 800309)
and a LiposoFast extruder device (Sigma-Aldrich) to generate large
unilamellar vesicles.
Cell survival
Bone marrow-derived macrophages were washed and resuspended
in culture media and plated in a 96-well plate that was pre-coated
with a titration of mouse Trem2 antibody clone 4D9 (hIgG1-effector-
less) or isotype control overnight at 4°C. Antibody-coated plates
were washed with PBS twice, and cells were plated in media with a
low concentration of M-CSF (5 ng/ml, Gibco, Cat# PHC9501). After
5 days, cellular ATP levels were measured by luminescence detec-
tion to indicate cell viability with CellTiter-Glo (Promega Catalog
Number G7571).
Myelin, Ab, and E. coli phagocytosis by primary microglia
Postnatal microglia were isolated with the Neural Tissue Dissocia-
tion Kit (Miltenyi Biotec, Cat# 130-092-628) and anti-CD11b
magnetic beads (Miltenyi Biotec, Cat# 130-049-601) according to the
manufacturer’s instructions. Briefly, brains from p7-p10 animals
were dissociated to a single-cell suspension, which was then passed
through a 70-lm strainer. The cells were then washed by repeated
centrifugation at 300 g and incubated with the CD11b+ beads for
15 min on ice. The suspension was then passed through the LS
Column (Miltenyi Biotec, Cat# 130-042-401) on the magnet to isolate
CD11b+ cells. The cells were plated in growth media: DMEM
supplemented with high glucose, sodium pyruvate, penicillin/strep-
tomycin, 10% fetal calf serum, and 10% of media conditioned by
the CSF1-expressing l,929 cells. The cells were allowed to grow to
full confluence. On the day before the experiment, the media were
changed to TIC media: DMEM containing human TGF-b2 (2 ng/ml,
PeproTech, Cat# 100-35B), murine IL-34 (100 ng/ml, R&D Systems,
Cat# 5195-ML-010), and cholesterol (1.5 lg/ml, Avanti Polar Lipids,
Cat# 700000p-1g) (Bohlen et al, 2017). Treatment with 4D9 and
isotype control antibodies (both at 20 lg/ml) was performed over-
night in TIC media. The various substrates were added for the indi-
cated times before fixation in 4% paraformaldehyde for 15 min.
Myelin was labeled with the PKH26 kit (Sigma, Cat# PKH26GL-
1KT). Briefly, 250 lg of myelin was resuspended in solution C from
the kit and the dye PKH26 was added to the mix. After 5 min,
myelin was centrifuged and washed in sterile PBS. One micromolar
human Ab(1–42)-HiLyte (Anaspec Inc.) and E. coli pHrodo (Thermo
Fisher Scientific) were prepared as previously described (Klein-
berger et al, 2014). The cells were stained with isolectin conjugated
to DyLight 649 (Vectorlabs, Cat# DL-1208) for 60 min at room
temperature and with Hoechst 33342 for 10 min before mounting.
The stained cells were then imaged on a Leica sp5 confocal micro-
scope with a 63× objective. At least three fields per condition were
recorded, and the number of substrate-positive cells was normalized
to the total number of cells. The cells treated with each specific
Kai Schlepckow et al EMBO Molecular Medicine
ª 2020 The Authors EMBO Molecular Medicine 12: e11227 | 2020 17 of 22
substrate in the absence of the antibody were used as the baseline
for the same treatment in the presence of the 4D9 or the RSV isotype
control antibody. The final graph shows the average increment in
the uptake of various substrates after antibody treatment in three
independent experiments.
Mouse lines
Wild-type C57BL/6J mice used for pharmacokinetic analysis of anti-
bodies were purchased from the Jackson Laboratory at 2 months of
age. Wild-type C57BL/6J mice as used for immunoblot and MSD
ELISA analyses of BMDM in Fig 3B and C were purchased from
Charles River and were 2.5–3 months of age when sacrificed.
TREM2 KO mice on C57BL/6J background were originally received
from Marco Colonna (Turnbull et al, 2006; Mazaheri et al, 2017).
An additional TREM2 KO mouse line used for BMDM and primary
microglia culture-related experiments in Figs 3A and D, and 4A was
purchased from Jackson Laboratory (Stock#027197) and back-
crossed to C57BL/6J to generate TREM2 KO heterozygous mice and
then intercrossed the heterozygous mice together to generate
TREM2 KO and littermate wild-type control. These mice were at
least 2.5 months of age when they were sacrificed. To investigate
4D9 modulatory effects on TREM2 and P2RY12 by immunohisto-
chemistry, we used the APP-NL-G-F knock-in mice described by
Saido and colleagues (Saito et al, 2014). All mouse husbandry and
experimental procedures were approved by Denali Institutional
Animal Care and Use Committee. Similarly, all animal experiments
at DZNE were performed in accordance with animal-handling laws
of the state of Bavaria (Germany). Housing conditions included
standard pellet food and water provided ad libitum, a 12-h light–
dark cycle at temperature of 22°C with maximal 5 mice per cage and
cage replacement once per week, and regular health monitoring.
Dosing APP-NL-G-F mice with 4D9-effectorless antibody
Six-month-old APP-NL-G-F (Apptm3.1Tcs/Apptm3.1Tcs) and age-
matched C57BL/6J wild-type (WT) mice were randomly allocated to
either isotype control or 4D9 antibody treatment group. Both male
and female mice were used for either genotype. Mice were weighed
and then intraperitoneally injected with 50 mg/kg isotype control or
4D9 antibody on days 0, 3, 6, and 9, and the study was terminated
on day 10.
Antibody pharmacokinetics
C57BL/6J mice were dosed with 4D9-hIgG-effectorless antibody or
control IgG at 10 mg/kg through the intravenous (IV) tail vein injec-
tion. Blood samples were collected at 1 h, 24 h, day 4, and day 7
after dosing. The in-life blood at the first three time points was
collected through the submandibular bleeding, and the terminal
blood at day 7 was collected through the cardiac puncture. Blood
was collected in EDTA tube (Sarstedt Microvette 500 K3E) with
slowly inverting for 10 times and then centrifuged at 15,350 g for
7 min at 4°C. Plasma (top layer) was transferred to 1.5-ml Eppen-
dorf tube and stored at 80°C until measurement.
Human IgG antibody concentration was measured using a stan-
dard colorimetric ELISA. 384w MaxiSorp plates were coated with
donkey anti-human IgG capture antibody (Jackson
ImmunoResearch) diluted to 1 lg/ml in sodium bicarbonate and
incubated overnight at 4°C. The following morning, plates were
washed 3× with PBST and blocked with 5% BSA/PBST solution for
1 h at RT. Plates were washed again before addition of sample.
Samples were incubated on the plate for 2 h at RT. To detect, plates
were washed and goat anti-human IgG-HRP (Jackson ImmunoRe-
search) diluted 1:40,000 in 1% BSA/PBST solution was added to
each well and incubated for 2 h at RT. Plates were then washed,
developed with TMB substrate, and stopped with the addition of 2N
sulfuric acid. Absorbance was measured at 450 nm on the BioTek
plate reader.
Target engagement
The levels of bound (B) sTREM2 and total (T) sTREM2 were deter-
mined by measuring [4D9-bound ms-sTREM2] and [ms-sTREM2] in
samples using a sandwich-layout MSD as previously described. Each
biospecimen (plasma, CSF, or brain lysate) utilized the same MSD
TREM2 detection formats for the bound and total assay. For the
bound assay, [4D9-bound ms-sTREM2] is directly determined by
the sulfo-tagged detection-Ab against 4D9 (Tx-Ab). In the total
assay, adding additional Tx-Ab to the biofluid samples is required to
saturate any remaining unbound fraction of ms-sTREM2 in the
biofluids. After this step of Tx-Ab saturation, the total [ms-sTREM2]
can be measured by the same Sulfo-tagged Detection-Ab. The target
engagement (TE) levels for each biofluid sample can be represented
by the percentage of [BOUND sTREM2]/[TOTAL sTREM2] (B/T %).
Immunofluorescence analyses and confocal imaging of mouse
brain sections
Following cardiac perfusion with ice-cold PBS, left-brain hemi-
spheres were immerse-fixed in 4% paraformaldehyde for 24 h and
in 30% sucrose for 24 h subsequently. After freezing, 50-lm micro-
tome-cut free-floating sections were washed briefly and then blocked
using 5% donkey serum for 1 h at room temperature. Subsequently,
sections were incubated with primary antibodies (IBA1 1:300, Invit-
rogen, PA5-27436; Ab1–40 1:3,000, clone 3552 (Page et al, 2010), in-
house antibody) at 4°C overnight or (TREM2 1:50, R&D Systems,
AF1729; P2RY12 1:100, BioLegend, clone S16007D) over two nights
at 4°C. Sections were washed and incubated in donkey anti-rabbit
AF488 (1:1,000, Invitrogen, A32790) and AF647 (1:1,000, Invitro-
gen, A32795), donkey anti-rat AF488 (1:500, Invitrogen, A21208),
and donkey anti-sheep AF555 (1:500, Invitrogen, A21436) secondary
antibodies for 2 h at room temperature. Lastly, slides were washed
and stained with 40,6-diamidino-2-phenylindole (DAPI, 5 lg/ml)
before mounting coverslips with ProLongTM Gold antifade reagent
(Thermo Fisher Scientific). For all stainings, an average of three
sections per mouse was stained and quantified. Confocal images
were acquired using a LSM 800 confocal microscope (Zeiss) and the
ZEN 2.5 Zeiss software package. At least three images were taken to
include larger areas of the cortex using 10× (Plan-Apochromat 10×/
0.25) and 20× (Plan-Apochromat 20×/0.8) objectives at
2,048 × 2,048 pixel resolution with a z-step size of 1.1 lm at 18 lm
thickness. Leica DMi8 fluorescence microscope and Leica Applica-
tion Suite X software were used to acquire tile scan images of the
entire cortex using 10× objective (Plan-Apochromat 10×/0.32 PH1).
All P2RY12-positive cells per image were counted on FIJI software
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(ImageJ) using the “Cell counter” plugin. For IBA1, TREM2, and Ab
plaque coverage analyses, confocal acquired images for cortex were
imported into FIJI and channels were separated by “Image/Color/
Split Channels”. Following this, background noise was removed
using Gaussian filtering and intensity distribution for each image
was equalized using rolling ball algorithm. All layers from a single
image stack were projected on a single slice by “Stack/Z projection”.
Lastly, the stainings were segmented using automatic thresholding
method in FIJI (IBA1, “Moments”; TREM2, “MaxEntropy”; plaques,
“Triangle”). Coverage analysis indicates number of stained positive
pixels over total number of pixels in a given area. Plaque area was
measured in FIJI on thresholded images.
Biochemical characterization of brain tissue from
APP-NL-G-F mice
DEA (0.2% diethylamine in 50 mM NaCl, pH 10, and protease inhi-
bitor mix [Sigma, P8340]) and RIPA lysates (20 mM Tris–HCl [pH
7.5], 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% NP-40, 1%
sodium deoxycholate, 2.5 mM sodium pyrophosphate, and protease
inhibitor mix [Sigma, P8340]) were prepared from brain hemi-
spheres (Willem et al, 2015). RIPA lysates were centrifuged at
14,000 g (60 min at 4°C), and the remaining pellet was homoge-
nized in 70% formic acid (FA fraction). The FA fraction was neutral-
ized with 20× 1 M Tris–HCl buffer at pH 9.5 and used for Ab
analysis. For Ab detection, proteins were separated on Tris-Tricine
gels (10–20%, Thermo Fisher Scientific), transferred to nitrocellu-
lose membranes (0.1 lm, GE Healthcare), which were boiled for
5 min in PBS and subsequently incubated with the blocking solution
containing 0.2% I-Block (Thermo Fisher Scientific) and 0.1% Tween
20 (Merck) in PBS for 1 h, followed by overnight incubation with
2 lg/ml 2D8 antibody in the blocking solution. The rat monoclonal
2D8 antibody against Ab was described before (Shirotani et al,
2007). Ab in DEA and FA fractions was quantified by a sandwich
immunoassay using the Meso Scale Ab Triplex plates and Discovery
Sector Imager 2400 as described previously (Page et al, 2008).
Samples were measured in triplicates.
Statistical analyses
All statistical analyses were performed using GraphPad Prism 7.
Data are shown as mean  SEM or median  SEM. Whether data
were normally distributed was tested using the D’Agostino and
Pearson, Shapiro–Wilk, and Kolmogorov–Smirnov normality tests.
In case data were not normally distributed, we applied the Mann–
Whitney U-test as shown in Fig 7D, E and G. In all other data sets,
data were distributed normally. We therefore applied either t-test or
one-way ANOVA. When comparing multiple groups, two-way
ANOVA was applied. ANOVA analyses were always followed by
appropriate post hoc analyses. Regarding animal studies, sample
size was determined based on experience from previous findings
and animal availability, i.e., no power calculation was done prior to
study design. No specific randomization procedure was employed.
However, all animals were randomly assorted into treatment groups
after genotyping. Samples were pseudoanonymized. None of the
animals were excluded from analysis based on the results from
ROUT analysis to identify outliers on GraphPad Prism. Only in the
data of Fig 3B, we identified one outlier by ROUT analysis which
was therefore excluded from analysis. In the figures, statistical
evaluations are displayed as follows: *P < 0.05; **P < 0.01;
***P < 0.001; ****P < 0.0001; n.s., not significant (P > 0.05). All
data were generated from at least three independent biological
experiments or three mice per group unless otherwise stated.
Expanded View for this article is available online.
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The paper explained
Problem
Numerous clinical trials with amyloid b-peptide targeting strategies
failed to show cognitive improvement and sometimes even caused
adverse effects. Novel therapeutic targets and disease-modulating
strategies are therefore desperately required for treating neurodegen-
erative diseases, a significant global unmet medical need. The micro-
glial-expressed triggering receptor expressed on myeloid cells 2
(TREM2) is known to exert protective functions in the CNS, which are
diminished by disease-associated loss-of-function risk variants. We
therefore sought to identify monoclonal antibodies capable of enhanc-
ing TREM2 function on microglia.
Results
Monoclonal antibodies raised against the entire ectodomain of mouse
TREM2 were screened to identify those which increase TREM2 expres-
sion on the cell surface. Antibody discovery efforts identified clone
4D9, with an epitope in the stalk region of the TREM2 extracellular
domain, proximal to the ADAM cleavage site. The 4D9 antibody
elicited a strong increase in cell-surface TREM2 and concomitantly
reduced proteolytic shedding of soluble TREM2 (sTREM2). 4D9 acti-
vated TREM2-dependent phospho-SYK signaling in a dose-dependent
manner and enhanced TREM2 function resulting in profound survival
rescue with restricted M-CSF, increased phagocytosis of Ab and
myelin in vitro. In vivo target engagement was demonstrated by
nearly saturated binding of sTREM2 in CSF and by increased TREM2
and decreased P2RY12 expression in brains of 4D9-dosed mice.
Consistent with the induction of protective functions in microglia,
amyloidogenesis in a mouse model for Alzheimer’s pathology was
reduced following 4D9 treatment.
Impact
This is the first characterization of a TREM2 antibody’s mechanism of
action which elicits TREM2-dependent microglial activity. The function
enhancing TREM2 antibody binds to the stalk region of TREM2 near
the sheddase site and increases TREM2 signaling and cell-surface
receptor via bivalent interactions. These results support the therapeu-
tic hypothesis of enhancing TREM2 activity as a novel approach for
efficacious interventions for Alzheimer’s disease, and potentially other
neurodegenerative diseases as well as metabolic disorders associated
with obesity.
Kai Schlepckow et al EMBO Molecular Medicine
ª 2020 The Authors EMBO Molecular Medicine 12: e11227 | 2020 19 of 22
critically reading this manuscript. Joseph Duque and Tina Giese contributed to
antibody production and quality control of materials for in vitro and in vivo
studies. Lihong Zhan provided cells and reagents for in vitro studies. Hoang
Nguyen and Timothy Earr helped with in vivo studies.
Author contributions
CH, KS, JWL, and KMM conceived the study and analyzed the results. CH wrote
the manuscript with further input from JWL, KMM, GDP, MS, and KS. KS, GK,
NP, BB, JS, MW, HH, and RP performed the tissue culture experiments, Western
blot analyses, and ELISAs. XX provided BMDM. Monoclonal antibodies were
generated by RF and screened by GK, KS, and NP. AS purified monoclonal anti-
bodies from hybridoma supernatants. JIP sequenced and cloned hybridoma
antibodies. DJK performed Biacore analyses. CM led antibody production activ-
ities. FH advised on TE assay design and execution. DX performed studies in
mice, and HS and JS performed FACS analyses. C-CL developed the TE assay
and performed B/T% sTREM2 detection. MS and LC-C performed the uptake
assays using primary microglia. GW performed the uptake assays using BMDM,
and JS performed survival assays in BMDM. BN prepared liposomes and
performed ELISAs. ST contributed conceptually to the in vivo studies. GDP
contributed to in vivo studies design. SP performed immunohistochemistry on
brain sections.
Conflict of interest
C.H. collaborates with Denali Therapeutics, participated on one advisory board
meeting of Biogen, and received a speaker honorarium from Novartis and
Roche. C.H. is chief advisor of ISAR Bioscience. J.W.L., K.M.M., J.I.P., H.S., J.S., R.P.,
D.X., C.M., D.J.K., C.C.L., F.H., and G.D.P. are employees of Denali Therapeutics.
References
Bohlen CJ, Bennett FC, Tucker AF, Collins HY, Mulinyawe SB, Barres BA (2017)
Diverse requirements for microglial survival, specification, and function
revealed by defined-medium cultures. Neuron 94: 759 – 773.e758
Borroni B, Ferrari F, Galimberti D, Nacmias B, Barone C, Bagnoli S, Fenoglio C,
Piaceri I, Archetti S, Bonvicini C et al (2014) Heterozygous TREM2
mutations in frontotemporal dementia. Neurobiol Aging 35: 934 .e937–910
Bradbury A (2010) Antibody engineering, Vol. 1. Berlin Heidelberg: Springer-
Verlag
Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G,
Koeglsperger T, Dake B, Wu PM, Doykan CE et al (2014) Identification of a
unique TGF-beta-dependent molecular and functional signature in
microglia. Nat Neurosci 17: 131 – 143
Cantoni C, Bollman B, Licastro D, Xie M, Mikesell R, Schmidt R, Yuede CM,
Galimberti D, Olivecrona G, Klein RS et al (2015) TREM2 regulates
microglial cell activation in response to demyelination in vivo. Acta
Neuropathol 129: 429 – 447
Chan RB, Oliveira TG, Cortes EP, Honig LS, Duff KE, Small SA, Wenk MR, Shui
G, Di Paolo G (2012) Comparative lipidomic analysis of mouse and human
brain with Alzheimer disease. J Biol Chem 287: 2678 – 2688
Cheng Q, Danao J, Talreja S, Wen P, Yin J, Sun N, Li CM, Chui D, Tran D,
Koirala S et al (2018) TREM2-activating antibodies abrogate the negative
pleiotropic effects of the Alzheimer’s disease variant Trem 2(R47H) on
murine myeloid cell function. J Biol Chem 293: 12620 – 12633
Cochet O, Martin E, Fridman WH, Teillaud JL (1999) Selective PCR
amplification of functional immunoglobulin light chain from hybridoma
containing the aberrant MOPC 21-derived V kappa by PNA-mediated PCR
clamping. Biotechniques 26: 818 – 820, 822
Colonna M (2003) TREMs in the immune system and beyond. Nat Rev
Immunol 3: 445 – 453
Cuyvers E, Bettens K, Philtjens S, Van Langenhove T, Gijselinck I, van der
Zee J, Engelborghs S, Vandenbulcke M, Van Dongen J, Geerts N et al
(2014) Investigating the role of rare heterozygous TREM2 variants in
Alzheimer’s disease and frontotemporal dementia. Neurobiol Aging 35:
726 .e711–729
Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B,
van Dyck CH, Boada M et al (2019) Randomized trial of verubecestat for
prodromal Alzheimer’s disease. N Engl J Med 380: 1408 – 1420
Ewers M, Franzmeier N, Suarez-Calvet M, Morenas-Rodriguez E, Caballero
MAA, Kleinberger G, Piccio L, Cruchaga C, Deming Y, Dichgans M et al
(2019) Increased soluble TREM2 in cerebrospinal fluid is associated with
reduced cognitive and clinical decline in Alzheimer’s disease. Sci Transl
Med 11: eaav6221
Feuerbach D, Schindler P, Barske C, Joller S, Beng-Louka E, Worringer KA,
Kommineni S, Kaykas A, Ho DJ, Ye C et al (2017) ADAM17 is the main
sheddase for the generation of human triggering receptor expressed in
myeloid cells (hTREM2) ectodomain and cleaves TREM2 after Histidine
157. Neurosci Lett 660: 109 – 114
Focke C, Blume T, Zott B, Shi Y, Deussing M, Peters F, Schmidt C, Kleinberger
G, Lindner S, Gildehaus FJ et al (2019) Early and longitudinal microglial
activation but not amyloid accumulation predicts cognitive outcome in
PS2APP mice. J Nucl Med 60: 548 – 554
Gotzl JK, Brendel M, Werner G, Parhizkar S, Sebastian Monasor L,
Kleinberger G, Colombo AV, Deussing M, Wagner M, Winkelmann J et al
(2019) Opposite microglial activation stages upon loss of PGRN or
TREM2 result in reduced cerebral glucose metabolism. EMBO Mol Med
11: e9711
Griciuc A, Patel S, Federico AN, Choi SH, Innes BJ, Oram MK, Cereghetti G,
McGinty D, Anselmo A, Sadreyev RI et al (2019) TREM2 acts downstream
of CD33 in modulating microglial pathology in Alzheimer’s disease. Neuron
103: 820 – 835
Guerreiro R, Bilgic B, Guven G, Bras J, Rohrer J, Lohmann E, Hanagasi H,
Gurvit H, Emre M (2013) Novel compound heterozygous mutation in
TREM2 found in a Turkish frontotemporal dementia-like family. Neurobiol
Aging 34: 2890 .e2891–2895
Haass C, Selkoe DJ (1993) Cellular processing of beta-amyloid precursor
protein and the genesis of amyloid beta-peptide. Cell 75: 1039 – 1042
Jaitin DA, Adlung L, Thaiss CA, Weiner A, Li B, Descamps H, Lundgren P,
Bleriot C, Liu Z, Deczkowska A et al (2019) Lipid-associated macrophages
control metabolic homeostasis in a Trem2-dependent manner. Cell 178:
686 – 698
Jiang T, Tan L, Chen Q, Tan MS, Zhou JS, Zhu XC, Lu H, Wang HF, Zhang YD,
Yu JT (2016) A rare coding variant in TREM2 increases risk for Alzheimer’s
disease in Han Chinese. Neurobiol Aging 42: 217 . e211–213
Jonsson T, Stefansson K (2013) TREM2 and neurodegenerative disease. N Engl
J Med 369: 1568 – 1569
Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J,
Bjornsson S, Huttenlocher J, Levey AI, Lah JJ et al (2013) Variant of TREM2
associated with the risk of Alzheimer’s disease. N Engl J Med 368:
107 – 116
Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R,
Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B et al (2017) A unique
microglia type associated with restricting development of Alzheimer’s
disease. Cell 169: 1276 – 1290.e1217
Kim JH, Lee SR, Li LH, Park HJ, Park JH, Lee KY, Kim MK, Shin BA, Choi SY
(2011) High cleavage efficiency of a 2A peptide derived from porcine
EMBO Molecular Medicine Kai Schlepckow et al
20 of 22 EMBO Molecular Medicine 12: e11227 | 2020 ª 2020 The Authors
teschovirus-1 in human cell lines, zebrafish and mice. PLoS ONE 6:
e18556
Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E, Cuyvers E,
Struyfs H, Pettkus N, Wenninger-Weinzierl A, Mazaheri F et al (2014)
TREM2 mutations implicated in neurodegeneration impair cell surface
transport and phagocytosis. Sci Transl Med 6: 243ra286
Kleinberger G, Brendel M, Mracsko E, Wefers B, Groeneweg L, Xiang X, Focke
C, Deussing M, Suarez-Calvet M, Mazaheri F et al (2017) The FTD-like
syndrome causing TREM2 T66M mutation impairs microglia function,
brain perfusion, and glucose metabolism. EMBO J 36: 1837 – 1853
Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting
antibody of predefined specificity. Nature 256: 495 – 497
Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers
L, O’Loughlin E, Xu Y, Fanek Z et al (2017) The TREM2-APOE pathway
drives the transcriptional phenotype of dysfunctional microglia in
neurodegenerative diseases. Immunity 47: 566 – 581.e569
Kuhn PH, Colombo AV, Schusser B, Dreymueller D, Wetzel S, Schepers U,
Herber J, Ludwig A, Kremmer E, Montag D et al (2016) Systematic
substrate identification indicates a central role for the metalloprotease
ADAM10 in axon targeting and synapse function. Elife 5: e12748
Marschallinger JIT, Zardeneta M, Lee SE, Lehallier B, Haney MS, Pluvinage JV,
Mathur V, Hahn O, Morgens DW, Kim J et al (2020) Lipid droplet
accumulating microglia represent a dysfunctional and pro-inflammatory
state in the aging brain. Nat Neurosci 23: 194 – 208
Mazaheri F, Snaidero N, Kleinberger G, Madore C, Daria A, Werner G,
Krasemann S, Capell A, Trumbach D, Wurst W et al (2017) TREM2
deficiency impairs chemotaxis and microglial responses to neuronal injury.
EMBO Rep 18: 1186 – 1198
Monasor LSMSA, Colombo A, König J, Roth S, Liesz A, Berghofer A, Saito T,
Saido TC, Herms J, Willem M et al (2019) Fibrillar Abeta triggers microglial
proteome alterations and dysfunction in Alzheimer mouse models. bioRxiv
https://doi.org/10.1101/861146 [PREPRINT]
Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, Maier P, Rueger P,
Stracke JO, Lau W, Tissot AC et al (2014) Increased brain penetration and
potency of a therapeutic antibody using a monovalent molecular shuttle.
Neuron 81: 49 – 60
Nugent AA, Lin K, van Lengerich B, Lianoglou S, Przybyla L, Davis SS,
Llapashtica C, Wang J, Kim DJ, Xia D et al (2019) TREM2 regulates
microglial cholesterol metabolism upon chronic phagocytic challenge.
Neuron 105: 837 – 854
O’Koren EG, Yu C, Klingeborn M, Wong AYW, Prigge CL, Mathew R, Kalnitsky J,
Msallam RA, Silvin A, Kay JN et al (2019) Microglial function is distinct in
different anatomical locations during retinal homeostasis and
degeneration. Immunity 50: 723 – 737.e727
Page RM, Baumann K, Tomioka M, Perez-Revuelta BI, Fukumori A, Jacobsen
H, Flohr A, Luebbers T, Ozmen L, Steiner H et al (2008) Generation of
Abeta38 and Abeta42 is independently and differentially affected by
familial Alzheimer disease-associated presenilin mutations and gamma-
secretase modulation. J Biol Chem 283: 677 – 683
Page RM, Gutsmiedl A, Fukumori A, Winkler E, Haass C, Steiner H (2010)
Beta-amyloid precursor protein mutants respond to gamma-secretase
modulators. J Biol Chem 285: 17798 – 17810
Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C,
Nuscher B, Xiong M, Ghasemigharagoz A, Katzmarski N et al (2019) Loss
of TREM2 function increases amyloid seeding but reduces plaque-
associated ApoE. Nat Neurosci 22: 191 – 204
Ransohoff RM (2016) How neuroinflammation contributes to
neurodegeneration. Science 353: 777 – 783
Rayaprolu S, Mullen B, Baker M, Lynch T, Finger E, Seeley WW, Hatanpaa KJ,
Lomen-Hoerth C, Kertesz A, Bigio EH et al (2013) TREM2 in
neurodegeneration: evidence for association of the p. R47H variant with
frontotemporal dementia and Parkinson’s disease. Mol Neurodegener 8: 19
Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, Iwata N, Saido
TC (2014) Single App knock-in mouse models of Alzheimer’s disease. Nat
Neurosci 17: 661 – 663
Schlepckow K, Kleinberger G, Fukumori A, Feederle R, Lichtenthaler SF, Steiner
H, Haass C (2017) An Alzheimer-associated TREM2 variant occurs at the
ADAM cleavage site and affects shedding and phagocytic function. EMBO
Mol Med 9: 1356 – 1365
Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, Dunstan R,
Salloway S, Chen T, Ling Y et al (2016) The antibody aducanumab reduces
Abeta plaques in Alzheimer’s disease. Nature 537: 50 – 56
Shirotani K, Tomioka M, Kremmer E, Haass C, Steiner H (2007) Pathological
activity of familial Alzheimer’s disease-associated mutant presenilin can
be executed by six different gamma-secretase complexes. Neurobiol Dis 27:
102 – 107
Shirotani K, Hori Y, Yoshizaki R, Higuchi E, Colonna M, Saito T, Hashimoto S,
Saito T, Saido TC, Iwata N (2019) Aminophospholipids are signal-
transducing TREM2 ligands on apoptotic cells. Sci Rep 9: 7508
Song WM, Joshita S, Zhou Y, Ulland TK, Gilfillan S, Colonna M (2018)
Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of
R47H polymorphism. J Exp Med 215: 745 – 760
Suarez-Calvet M, Araque Caballero MA, Kleinberger G, Bateman RJ, Fagan AM,
Morris JC, Levin J, Danek A, Ewers M, Haass C et al (2016a) Early changes
in CSF sTREM2 in dominantly inherited Alzheimer’s disease occur after
amyloid deposition and neuronal injury. Sci Transl Med 8: 369ra178
Suarez-Calvet M, Kleinberger G, Araque Caballero MA, Brendel M, Rominger A,
Alcolea D, Fortea J, Lleo A, Blesa R, Gispert JD et al (2016b) sTREM2
cerebrospinal fluid levels are a potential biomarker for microglia activity
in early-stage Alzheimer’s disease and associate with neuronal injury
markers. EMBO Mol Med 8: 466 – 476
Suarez-Calvet M, Morenas-Rodriguez E, Kleinberger G, Schlepckow K, Araque
Caballero MA, Franzmeier N, Capell A, Fellerer K, Nuscher B, Eren E et al
(2019) Early increase of CSF sTREM2 in Alzheimer’s disease is associated
with tau related-neurodegeneration but not with amyloid-beta pathology.
Mol Neurodegener 14: 1
Thornton P, Sevalle J, Deery MJ, Fraser G, Zhou Y, Stahl S, Franssen EH, Dodd
RB, Qamar S, Gomez Perez-Nievas B et al (2017) TREM2 shedding by
cleavage at the H157-S158 bond is accelerated for the Alzheimer’s
disease-associated H157Y variant. EMBO Mol Med 9: 1366 – 1378
Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, Hernandez M,
Colonna M (2006) Cutting edge: TREM-2 attenuates macrophage
activation. J Immunol 177: 3520 – 3524
Ulland TK, Wang Y, Colonna M (2015) Regulation of microglial survival and
proliferation in health and diseases. Semin Immunol 27: 410 – 415
Ulland TK, Song WM, Huang SC, Ulrich JD, Sergushichev A, Beatty WL, Loboda
AA, Zhou Y, Cairns NJ, Kambal A et al (2017) TREM2 maintains microglial
metabolic fitness in Alzheimer’s disease. Cell 170: 649 – 663.e613
Ulrich JD, Ulland TK, Colonna M, Holtzman DM (2017) Elucidating the role of
TREM2 in Alzheimer’s disease. Neuron 94: 237 – 248
Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S,
Krishnan GM, Sudhakar S, Zinselmeyer BH et al (2015) TREM2 lipid
sensing sustains the microglial response in an Alzheimer’s disease model.
Cell 160: 1061 – 1071
Willem M, Tahirovic S, Busche MA, Ovsepian SV, Chafai M, Kootar S,
Hornburg D, Evans LD, Moore S, Daria A et al (2015) g-Secretase
Kai Schlepckow et al EMBO Molecular Medicine
ª 2020 The Authors EMBO Molecular Medicine 12: e11227 | 2020 21 of 22
processing of APP inhibits neuronal activity in the hippocampus. Nature
526: 443 – 447
Wunderlich P, Glebov K, Kemmerling N, Tien NT, Neumann H, Walter J (2013)
Sequential proteolytic processing of the triggering receptor expressed on
myeloid cells-2 (TREM2) protein by ectodomain shedding and gamma-
secretase-dependent intramembranous cleavage. J Biol Chem 288: 33027– 33036
Xiang X, Werner G, Bohrmann B, Liesz A, Mazaheri F, Capell A, Feederle R, Knuesel
I, Kleinberger G, Haass C (2016) TREM2 deficiency reduces the efficacy of
immunotherapeutic amyloid clearance. EMBO Mol Med 8: 992 –1004
Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, Atwal J, Elliott JM,
Prabhu S, Watts RJ et al (2011) Boosting brain uptake of a therapeutic
antibody by reducing its affinity for a transcytosis target. Sci Transl
Med 3: 84ra44
Zhong L, Chen XF, Wang T, Wang Z, Liao C, Wang Z, Huang R, Wang D, Li X,
Wu L et al (2017) Soluble TREM2 induces inflammatory responses and
enhances microglial survival. J Exp Med 214: 597 – 607
Zhong L, Xu Y, Zhuo R, Wang T, Wang K, Huang R, Wang D, Gao Y, Zhu Y,
Sheng X et al (2019) Soluble TREM2 ameliorates pathological phenotypes
by modulating microglial functions in an Alzheimer’s disease model. Nat
Commun 10: 1365
License: This is an open access article under the
terms of the Creative Commons Attribution 4.0
License, which permits use, distribution and reproduc-
tion in any medium, provided the original work is
properly cited.
22 of 22 EMBO Molecular Medicine 12: e11227 | 2020 ª 2020 The Authors
EMBO Molecular Medicine Kai Schlepckow et al
